Benson Hill (BHIL) 10-Q 10 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 08, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-39835
Entity Registrant Name	Benson Hill, Inc.
Entity Incorporation, State Code	DE
Entity Tax Identification Number	85-3374823
Entity Address, Address Line One	1001 North Warson Rd
Entity Address, City or Town	St. Louis,
Entity Address, State or Province	MO
Entity Address, Postal Zip Code	63132
City Area Code	(314)
Local Phone Number	222-8218
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		205,659,767
Entity Central Index Key	0001830210
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Stock, $0.0001 par value
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	BHIL
Security Exchange Name	NYSE
Warrants exercisable for one share of common stock at an exercise price of $11.50
Entity Information [Line Items]
Title of 12(b) Security	Warrants exercisable for one share of common stock at an exercise price of $11.50
Trading Symbol	BHIL WS
Security Exchange Name	NYSE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 46,772	$ 78,963
Marketable securities	163,135	103,689
Accounts receivable, net	36,753	31,729
Inventories, net	47,766	48,724
Prepaid expenses and other current assets	14,544	20,253
Total current assets	308,970	283,358
Property and equipment, net	124,762	126,885
Right of use asset, net	74,337	77,452
Goodwill and intangible assets, net	42,665	42,664
Other assets	4,541	4,538
Total assets	555,275	534,897
Current liabilities:
Accounts payable	21,826	35,508
Revolving line of credit	755	47
Current lease liability	3,039	2,422
Current maturities of long-term debt	25,776	6,934
Accrued expenses and other current liabilities	27,423	26,771
Total current liabilities	78,819	71,682
Long-term debt	83,458	77,170
Long-term lease liability	79,599	79,154
Warrant liabilities	32,857	46,051
Conversion option liability	10,940	8,783
Deferred tax liability	304	294
Other non-current liabilities	318	316
Total liabilities	286,295	283,450
Stockholders’ equity:
Redeemable convertible preferred stock, $0.001 par value; 1,000 and 1,000 shares authorized, 0 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	0	0
Common stock, $0.0001 par value, 440,000 and 440,000 shares authorized, 205,616 and 178,089 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	21	18
Additional paid-in capital	600,736	533,101
Accumulated deficit	(324,699)	(280,569)
Accumulated other comprehensive loss	(7,078)	(1,103)
Total stockholders’ equity	268,980	251,447
Total liabilities and stockholders’ equity	$ 555,275	$ 534,897

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Redeemable convertible preferred stock, par value (in usd per share)	$ 0.001	$ 0.001
Redeemable convertible preferred stock, par value (in shares)	1,000,000	1,000,000
Redeemable convertible preferred stock, shares, issued (in shares)	0	0
Redeemable convertible preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	440,000,000	440,000,000
Common stock, shares, issued (in shares)	205,616,000	178,089,000
Common stock, shares outstanding (in shares)	205,616,000	178,089,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenues	$ 110,747	$ 39,692	$ 203,192	$ 71,494
Cost of sales	105,171	39,722	202,838	70,955
Gross profit (loss)	5,576	(30)	354	539
Operating expenses:
Research and development	12,017	8,818	24,323	15,945
Selling, general and administrative expenses	22,494	15,761	45,618	29,494
Total operating expenses	34,511	24,579	69,941	45,439
Loss from operations	(28,935)	(24,609)	(69,587)	(44,900)
Other (income) expense:
Interest expense, net	3,524	1,277	9,912	2,535
Change in fair value of warrants	(5,899)	1,703	(37,640)	2,719
Other expense (income), net	938	(170)	2,254	(388)
Total other (income) expense, net	(1,437)	2,810	(25,474)	4,866
Net loss before income tax	(27,498)	(27,419)	(44,113)	(49,766)
Income tax (benefit) expense	56	0	17	0
Net loss	$ (27,554)	$ (27,419)	$ (44,130)	$ (49,766)
Net loss per common share:
Basic loss per common share (in usd per share)	$ (0.15)	$ (0.25)	$ (0.25)	$ (0.46)
Diluted loss per common share (in usd per share)	$ (0.15)	$ (0.25)	$ (0.25)	$ (0.46)
Weighted average shares outstanding:
Basic weighted average shares outstanding (in shares)	185,530	109,222	173,189	108,989
Diluted weighted average shares outstanding (in shares)	185,530	109,222	173,189	108,989

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (27,554)	$ (27,419)	$ (44,130)	$ (49,766)
Foreign currency:
Comprehensive income (loss)	20	70	(45)	(1)
Marketable securities:
Comprehensive (loss) income	(4,393)	358	(8,159)	271
Adjustment for net losses (income) realized in net loss	1,022	(300)	2,229	(347)
Other comprehensive loss	(3,371)	58	(5,930)	(76)
Total other comprehensive (loss) income	(3,351)	128	(5,975)	(77)
Total comprehensive loss	$ (30,905)	$ (27,291)	$ (50,105)	$ (49,843)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Previously Reported	Retroactive application of recapitalization	Common Stock	Common Stock Previously Reported	Common Stock Retroactive application of recapitalization	Additional Paid-In Capital	Additional Paid-In Capital Previously Reported	Additional Paid-In Capital Retroactive application of recapitalization	Accumulated Deficit	Accumulated Deficit Previously Reported	Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Previously Reported
Beginning balance (in shares) at Dec. 31, 2020	0	102,899	(102,899)
Beginning balance at Dec. 31, 2020	$ 0	$ 287,323	$ (287,323)
Ending balance (in shares) at Mar. 31, 2021	0
Ending balance at Mar. 31, 2021	$ 0
Beginning balance (in shares) at Dec. 31, 2020				108,697	5,798	102,899
Beginning balance at Dec. 31, 2020	132,682	$ (154,641)	$ 287,323	$ 11	$ 1	$ 10	$ 287,318	$ 5	$ 287,313	$ (154,322)	$ (154,322)	$ (325)	$ (325)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)				136
Issuance of common stock upon exercise of stock options	85						85
Stock-based compensation expense	647						647
Other	(16)						(15)			(1)
Comprehensive loss	(22,552)									(22,347)		(205)
Ending balance (in shares) at Mar. 31, 2021				108,833
Ending balance at Mar. 31, 2021	$ 110,846			$ 11			288,035			(176,670)		(530)
Beginning balance (in shares) at Dec. 31, 2020	0	102,899	(102,899)
Beginning balance at Dec. 31, 2020	$ 0	$ 287,323	$ (287,323)
Ending balance (in shares) at Jun. 30, 2021	0
Ending balance at Jun. 30, 2021	$ 0
Beginning balance (in shares) at Dec. 31, 2020				108,697	5,798	102,899
Beginning balance at Dec. 31, 2020	132,682	$ (154,641)	$ 287,323	$ 11	$ 1	$ 10	287,318	$ 5	$ 287,313	(154,322)	$ (154,322)	(325)	$ (325)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive loss	(49,843)
Ending balance (in shares) at Jun. 30, 2021				109,414
Ending balance at Jun. 30, 2021	$ 84,673			$ 11			289,153			(204,089)		(402)
Beginning balance (in shares) at Mar. 31, 2021	0
Beginning balance at Mar. 31, 2021	$ 0
Ending balance (in shares) at Jun. 30, 2021	0
Ending balance at Jun. 30, 2021	$ 0
Beginning balance (in shares) at Mar. 31, 2021				108,833
Beginning balance at Mar. 31, 2021	110,846			$ 11			288,035			(176,670)		(530)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)				581
Issuance of common stock upon exercise of stock options	409						409
Stock-based compensation expense	709						709
Comprehensive loss	(27,291)									(27,419)		128
Ending balance (in shares) at Jun. 30, 2021				109,414
Ending balance at Jun. 30, 2021	$ 84,673			$ 11			289,153			(204,089)		(402)
Beginning balance (in shares) at Dec. 31, 2021	0
Beginning balance at Dec. 31, 2021	$ 0
Ending balance (in shares) at Mar. 31, 2022	0
Ending balance at Mar. 31, 2022	$ 0
Beginning balance (in shares) at Dec. 31, 2021				178,089
Beginning balance at Dec. 31, 2021	251,447			$ 18			533,101			(280,569)		(1,103)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options and warrants (in shares)				830
Issuance of common stock upon exercise of stock options and warrants	636						636
Stock-based compensation expense	5,683						5,683
PIPE Investment, net of issuance costs (in shares)				26,150
PIPE Investment, net of issuance costs	54,928			$ 3			54,925
Comprehensive loss	(19,200)									(16,576)		(2,624)
Ending balance (in shares) at Mar. 31, 2022				205,069
Ending balance at Mar. 31, 2022	$ 293,494			$ 21			594,345			(297,145)		(3,727)
Beginning balance (in shares) at Dec. 31, 2021	0
Beginning balance at Dec. 31, 2021	$ 0
Ending balance (in shares) at Jun. 30, 2022	0
Ending balance at Jun. 30, 2022	$ 0
Beginning balance (in shares) at Dec. 31, 2021				178,089
Beginning balance at Dec. 31, 2021	251,447			$ 18			533,101			(280,569)		(1,103)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive loss	(50,105)
Ending balance (in shares) at Jun. 30, 2022				205,616
Ending balance at Jun. 30, 2022	$ 268,980			$ 21			600,736			(324,699)		(7,078)
Beginning balance (in shares) at Mar. 31, 2022	0
Beginning balance at Mar. 31, 2022	$ 0
Ending balance (in shares) at Jun. 30, 2022	0
Ending balance at Jun. 30, 2022	$ 0
Beginning balance (in shares) at Mar. 31, 2022				205,069
Beginning balance at Mar. 31, 2022	293,494			$ 21			594,345			(297,145)		(3,727)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)				547
Issuance of common stock upon exercise of stock options	715						715
Stock-based compensation expense	5,676						5,676
Comprehensive loss	(30,905)									(27,554)		(3,351)
Ending balance (in shares) at Jun. 30, 2022				205,616
Ending balance at Jun. 30, 2022	$ 268,980			$ 21			$ 600,736			$ (324,699)		$ (7,078)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) (Parenthetical) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Statement of Stockholders' Equity [Abstract]
Transaction costs	$ 3,456

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Net loss	$ (44,130)	$ (49,766)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	10,942	5,430
Stock-based compensation expense	11,359	1,356
Bad debt expense	445	0
Change in fair value of warrants and conversion option	(37,640)	2,719
Accretion and amortization related to financing activities	5,875	805
Other	5,750	149
Changes in operating assets and liabilities:
Accounts receivable	(5,469)	(8,173)
Inventories	9,117	63
Prepaid expenses and other current assets	5,293	(4,520)
Accounts payable	(12,722)	3,799
Accrued expenses	(7,552)	881
Net cash used in operating activities	(58,732)	(47,257)
Investing activities
Purchases of marketable securities	(248,637)	(81,604)
Proceeds from maturities of marketable securities	9,549	2,050
Proceeds from sales of marketable securities	170,217	150,006
Payments for acquisitions of property and equipment	(5,637)	(21,128)
Payments made in connection with business acquisitions	(1,034)	0
Net cash (used in) provided by investing activities	(75,542)	49,324
Financing activities
Contributions from PIPE Investment, net of transaction costs of $3,761	81,234	0
Principal payments on debt	(4,576)	(1,794)
Proceeds from issuance of debt	24,040	0
Borrowing under revolving line of credit	12,491	14,451
Repayments under revolving line of credit	(11,783)	(11,481)
Repayments of financing lease obligations	(629)	(165)
Payment of deferred offering costs	0	(322)
Proceeds from the exercise of stock options and warrants	1,351	494
Net cash provided by financing activities	102,128	1,183
Effect of exchange rate changes on cash	(45)	(1)
Net (decrease) increase in cash and cash equivalents	(32,191)	3,249
Cash and cash equivalents, beginning of period	78,963	9,743
Cash and cash equivalents, end of period	46,772	12,992
Supplemental disclosure of cash flow information
Cash paid for taxes	1	0
Cash paid for interest	5,900	2,990
Supplemental disclosure of non-cash activities
PIPE Investment issuance costs included in accounts payable and accrued expenses and other current liabilities	362	0
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	2,255	2,995
Purchases of inventory included in accounts payable and accrued expenses and other current liabilities	10,013	2,170
Deferred offering costs included in accounts payable and accrued expenses and other current liabilities	0	2,139
Financing leases commencing in the period	$ 806	$ 0

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Statement of Cash Flows [Abstract]
Transaction costs	$ 3,761

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Benson Hill, Inc. and subsidiaries (collectively, “Benson Hill”, the “Company”, “we”, “us”, or “our”) are a values-driven food technology company with a vision to build a healthier and happier world by unlocking nature’s genetic diversity with our food innovation engine. Our purpose is to catalyze and broadly empower innovation from plant to plate so great tasting, more nutritious, affordable, and sustainable food choices are available to everyone. We combine cutting-edge technology with an innovative business approach to bring product innovations to customers and consumers. Our CropOS® technology platform uniquely combines data science, plant science, and food science to leverage the natural genetic diversity of plants to develop more innovative food, ingredient, and feed products — starting with a better seed. We are incorporated in Delaware and headquartered in St. Louis, Missouri, where the majority of our research and development activities are managed. We operate a soy crushing and food-grade white flake and soy flour manufacturing operation in Creston, Iowa and a soy crushing facility in Seymour, Indiana to sell our proprietary products and non-proprietary products in North America and in select international markets. We also process yellow peas in North Dakota and supply fresh produce through packing, distribution, and growing locations in the southeastern states of the United States. Merger with Star Peak Corp II On September 29, 2021 (the “Closing Date”), Star Peak Corp II (“STPC”), a special purpose acquisition company, consummated the previously announced merger (the “Closing”) pursuant to that certain Agreement and Plan of Merger, dated May 8, 2021 (the “Merger Agreement”), by and among STPC, STPC Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of STPC (“Merger Sub”), and Benson Hill, Inc., a Delaware corporation (“Legacy Benson Hill”). Pursuant to the terms of the Merger Agreement, a business combination between STPC and Legacy Benson Hill was effected through the merger of Merger Sub with and into Legacy Benson Hill, with Legacy Benson Hill surviving the transaction as a wholly-owned subsidiary of STPC (the “Merger”). On the Closing Date, STPC changed its name to Benson Hill, Inc (“New Benson Hill”) and Legacy Benson Hill changed its name to Benson Hill Holdings, Inc. The Merger was accounted for as a reverse recapitalization (the “Reverse Recapitalization”) in accordance with U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”). Under this method of accounting, STPC is treated as the “acquired” company and Legacy Benson Hill is treated as the acquirer for financial reporting purposes. The Reverse Recapitalization was treated as the equivalent of Legacy Benson Hill issuing stock for the net assets of STPC, accompanied by a recapitalization. The net assets of STPC are stated at historical cost, with no goodwill or other intangible assets recorded. This accounting treatment determination was primarily based on the following: • Legacy Benson Hill’s existing stockholders hold the majority of voting rights in New Benson Hill and are the largest single voting interest block in New Benson Hill; • Legacy Benson Hill’s senior management comprises all of the senior management of New Benson Hill; • The directors nominated by Legacy Benson Hill represent the majority of the directors on the board of directors of New Benson Hill; and • Legacy Benson Hill’s operations comprise the ongoing operations of New Benson Hill. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Legacy Benson Hill. The shares and corresponding capital amounts and losses per share, prior to the Merger, have been retroactively restated based on shares reflecting the exchange ratio established in the Merger. Activity within the Condensed Consolidated Statements of Stockholders’ Equity for the issuance and repurchases of Legacy Benson Hill redeemable convertible preferred stock (the “Legacy Benson Hill Preferred Stock”) was also retroactively converted to Legacy Benson Hill common stock (the “Legacy Benson Hill Common Stock”). Liquidity and Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP for interim financial reporting and Securities and Exchange Commission regulations, assuming the Company will continue as a going concern. For the three and six months ended June 30, 2022, the Company incurred a net loss of $27,554 and $44,130, respectively, and for the six months ended June 30, 2022, the Company had negative cash flows from operating activities of $58,732 and capital expenditures of $5,637. Furthermore, at June 30, 2022, the Company had term debt and notes payable of $109,234, and an accumulated deficit of $324,699. However, as of June 30, 2022 the Company had cash and cash equivalents of $46,772 and marketable securities of $163,135. As such, the Company believes that its cash and marketable securities position is sufficient to meet capital and liquidity requirements for at least the next 12 months after the date that the financial statements are available to be issued. The Company’s business prospects are subject to risks, expenses, and uncertainties frequently encountered by companies in the early stages of commercial operations. As of June 30, 2022 the Company has multiple debt instruments (see Note 11 — Debt ), including term loans, notes payable and a revolving line of credit, certain of which require adherence to financial covenants, including maintaining minimum liquidity and maintenance of a minimum cash balance. If the Company breaches these covenants, the holder of the debt may declare all amounts immediately due and payable. If the covenants are breached, the Company plans to attempt to secure a waiver of the covenants or an amendment that modifies the covenants but there are no assurances that the Company will be able to comply with its future covenants without such a waiver or that the Company will be successful in obtaining a waiver or an amendment during 2022 or 2023. On June 30, 2022, the Company signed an amendment to the Convertible Loan and Security Agreement, which modified the gross margin definition enabling the Company to draw on the second tranche of $20 million per the initial agreement. On June 30, 2022 the Company drew on the full $20 million. The attainment of profitable operations is also dependent upon future events, including obtaining adequate financing to complete and commercialize the Company’s research and development activities, obtaining adequate grower relationships, building its customer base, successfully executing its business and marketing strategy, and hiring appropriate personnel.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial reporting and Securities and Exchange Commission regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year ended December 31, 2022. A description of the Company’s significant accounting policies is included in the notes to our audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021. These unaudited condensed consolidated financial statements should be read in conjunction with the December 31, 2021 audited consolidated financial statements and the notes thereto. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and an Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain prior period balances have been reclassified to conform to the current period presentation in the unaudited condensed consolidated financial statements and the accompanying notes. All dollar and share amounts are in thousands, except per share and per unit amounts, unless otherwise noted. Share and per share amounts are presented on a post-conversion basis for all periods presented, unless otherwise specified. Emerging Growth Company and Smaller Reporting Company Status We are an “emerging growth company”, as defined in Section 2(a) of the Securities Act and have elected to take advantage of the benefits of the extended transition period for new or revised financial accounting standards. We expect to remain an emerging growth company at least through the end of the 2023 fiscal year and expect to continue to take advantage of the benefits of the extended transition period, although we may decide to early adopt such new or revised accounting standards to the extent permitted by such standards. We expect to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and non-public companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). This may make it difficult or impossible to compare our financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions because of the potential differences in accounting standards used. In addition, we intend to rely on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an emerging growth company, we intend to rely on such exemptions, we are not required to, among other things: (a) provide an auditor’s attestation report on our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act; (b) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act; (c) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis); and (d) disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive Officer’s compensation to median employee compensation. We will remain an emerging growth company under the JOBS Act until the earliest of (a) December 31, 2026, (b) the last date of our fiscal year in which we have total annual gross revenue of at least $1.07 billion, (c) the date on which we are deemed to be a “large accelerated filer” under the rules of the SEC with at least $700.0 million of outstanding securities held by non-affiliates, or (d) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the previous three years. We are also a “smaller reporting company” as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as the market value of our voting and non-voting common equity held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our voting and non-voting common equity held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. The Company will no longer be a smaller reporting company as of December 31, 2022. Redeemable Convertible Preferred Stock Prior to the Merger, the Company recorded shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company applied the guidance in ASC 480-10-S99-3A, Accounting for Redeemable Equity Instruments , and therefore classified all outstanding redeemable convertible preferred stock as temporary equity. The redeemable convertible preferred stock was recorded outside of stockholders’ equity because, in the event of certain deemed liquidation events considered not solely within the Company’s control, such as a merger, acquisition, and sale of all or substantially all of the Company’s assets, the preferred stock would become redeemable at the option of the holders. In the event of a change of control of the Company, proceeds received from the sale of such shares would be distributed in accordance with the liquidation preferences set forth in the Company’s Amended and Restated Certificate of Incorporation then in effect. All redeemable convertible preferred stock previously classified as temporary equity was retroactively adjusted and reclassified to permanent equity as a result of the Merger. As a result of the Merger, each share of Legacy Benson Hill Preferred Stock that was then issued and outstanding was automatically converted into Legacy Benson Hill Common Stock, such that each converted share of Legacy Benson Hill Preferred Stock was no longer outstanding and ceased to exist. Each share of Legacy Benson Hill Common Stock, including the Legacy Benson Hill Common Stock issued upon conversion of Legacy Benson Hill Preferred Stock, was converted into and exchanged for 1.0754 (“the Exchange Ratio”) shares of New Benson Hill common stock (“New Benson Hill Common Stock”). The Exchange Ratio was established pursuant to the terms of the Merger Agreement. Business Combinations The Company allocates the purchase price of its acquisitions to the assets acquired and liabilities assumed based upon their respective fair values at the acquisition date. The Company utilizes management estimates and an independent third-party valuation firm to assist in determining these fair values. The excess of the acquisition price over the estimated fair value of the net assets acquired is recorded as goodwill. Goodwill is adjusted for any changes to acquisition date fair value amounts made within the measurement period. Acquisition-related transaction costs are recognized separately from the business combination and expensed as incurred. Recently Adopted Accounting Guidance In June 2016, the FASB issued ASU 2016-13, Financial Instruments  — Credit Losses (“ASU 2016-13” or “CECL”), which requires measurement and the recognition of expected credit losses for financial assets held. The standard requires the measurement of expected credit losses to be based on relevant information, including historical experience, current conditions and a forecast that is supportable. The Company adopted the standard in the first quarter of 2022, with minimal impact to our consolidated financial statements. As part of the adoption, the Company reviewed its’ portfolio of available-for-sale debt securities in an unrealized loss position, and assessed whether it intends to sell, or it is more likely than not that it will be required to sell before recovery of its’ amortized cost basis. Additionally, the Company evaluated whether the decline in fair value has resulted from credit losses or other factors by considering the extent to which the fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the Company compares the present value of the cash flows expected to be collected against the amortized cost basis. A credit loss is recorded if the present value of the cash flows is less than the amortized cost basis, limited by the amount that the fair value is less than the amortized cost basis. Upon adoption, the Company did not record an allowance for credit losses on its available-for-sale debt securities. Additionally, the Company reviewed its open trade receivables arising from contractual sales. As part of its analysis, the Company performs periodic credit reviews of all active customers, reviews all trade receivables greater than 90 days past due, calculates historical loss rates and reviews current payment trends of all customers. Recently Issued Accounting Guidance Not Yet Effective In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 applies only to contracts and hedging relationships that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued due to reference rate reform. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. We are currently evaluating our contracts and the optional expedients provided by the new standard. In August 2020, the FASB issued ASU 2020-06, Debt (“ASU 2020-06”). ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock. For convertible instruments with conversion features that are not required to be accounted for as derivatives under ASC 815, Derivatives and Hedging , or that do not result in substantial premiums accounted for as paid-in capital, the embedded conversion features no longer are separated from the host contract. The Company is currently evaluating the impact ASU 2020-06 will have on its condensed consolidated financial statements.

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combinations	Business Combinations Merger with Star Peak Corp II As discussed in Note 1, on September 29, 2021, STPC completed the business combination with Legacy Benson Hill through the Merger, with Legacy Benson Hill surviving the Merger as a wholly-owned subsidiary of STPC. At the effective time of the Merger (the “Effective Time”), each outstanding share of Legacy Benson Hill Common Stock, par value $0.001 per share, including Legacy Benson Hill Common Stock held by prior owners of Legacy Benson Hill Preferred Stock (in each case, other than shares owned by Legacy Benson Hill as treasury stock, dissenting shares and restricted shares) was canceled and converted into the right to receive the number of shares of New Benson Hill Common Stock, par value $0.0001 per share, in a ratio equal to 1.0754. In addition, as of the Effective Time, each stock option to purchase shares of Legacy Benson Hill Common Stock (each, a “Legacy Benson Hill Option”), whether vested or unvested, and each warrant issued by Legacy Benson Hill to purchase Legacy Benson Hill Common Stock and/or Legacy Benson Hill Preferred Stock (each, a “Legacy Benson Hill Warrant”) that was outstanding immediately prior to the Effective Time was, by virtue of the occurrence of the Effective Time and without any action on the part of Legacy Benson Hill, STPC or any holder of Legacy Benson Hill equity thereof, assumed and converted into a New Benson Hill Option or a New Benson Hill Warrant. Each Legacy Benson Hill Option was converted into an option to purchase a number of shares of New Benson Hill Common Stock equal to the number of shares of Legacy Benson Hill Common Stock subject to such Legacy Benson Hill Option immediately prior to the Effective Time multiplied by 1.0754 (rounded down to the nearest whole share) and at an exercise price per share of New Benson Hill Common Stock equal to the exercise price per share of Legacy Benson Hill Common Stock subject to such Legacy Benson Hill Option divided by 1.0754 (rounded up to the nearest whole cent) (each, a “New Benson Hill Option”). Each Legacy Benson Hill Warrant was converted into a warrant to purchase a number of shares of New Benson Hill Common Stock equal to the number of shares of Legacy Benson Hill Common Stock subject to such Legacy Benson Hill Warrant immediately prior to the Effective Time multiplied by 1.0754 (rounded down to the nearest whole share) and at an exercise price per share of New Benson Hill Common Stock equal to the exercise price per share of Legacy Benson Hill Common Stock and/or Legacy Benson Hill Preferred Stock subject to such Legacy Benson Hill Warrant divided by 1.0754 (rounded up to the nearest whole cent). In connection with the execution of the Merger Agreement, STPC entered into separate subscription agreements (each, a “Subscription Agreement”) with a number of investors (each a “Subscriber”), pursuant to which the Subscribers agreed to purchase, and STPC agreed to sell to the Subscribers, an aggregate of 22,500 shares of common stock (the “PIPE Shares”), for a purchase price of $10 per share and an aggregate purchase price of $225.0 million, in a private placement pursuant to the subscription agreements (the “PIPE”). The PIPE investment closed simultaneously with the consummation of the Merger. Prior to the Merger, STPC had outstanding 10,063 Public Warrants (the “Public Warrants”) and 6,553 Private Placement Warrants (the “Private Placement Warrants”), which were listed on the New York Stock Exchange under the symbol “STPC WS.” Upon the closing of the Merger, they became listed on the New York Stock Exchange under the symbol “BHIL WS.” The Warrants remain subject to the same terms and conditions as prior to the Merger. Upon the closing of the Merger, the Company’s certificate of incorporation was amended and restated to, among other things, increase the total number of authorized shares of all classes of capital stock to 441,000 shares, of which 440,000 shares were designated Common Stock, $0.0001 par value per share, and 1,000 shares designated Preferred Stock, $0.0001 par value per share. Acquisition of Soy Processing Facilities ZFS Creston On December 30, 2021, we completed the acquisition of a food-grade white flake and soy flour manufacturing operation and related assets through the acquisition of ZFS Creston, LLC, a Delaware limited liability company (“ZFS Creston”), for aggregate cash consideration of $103,099, which includes a working capital adjustment payment of $1,034 in Q1 2022. The soybean processing facility will process the Company’s proprietary soybean varieties for distribution to end customers. The acquisition of the food-grade white flake and soy flour manufacturing facility was accounted for as a business combination, and accordingly, the acquired assets and liabilities were recorded at their preliminary estimated fair value, as presented below: Estimated Fair Value at Assets: Cash and cash equivalents $ 56 Accounts receivable 10,729 Inventories 18,209 Prepaid expenses and other current assets 3,627 Property and equipment 60,000 Right of use asset 853 Other assets 2,000 Identified intangible assets 11,000 Goodwill 7,079 Total assets acquired 113,553 Liabilities: Accounts payable 4,661 Lease liability 853 Accrued expenses and other liabilities 4,940 Total liabilities assumed 10,454 Total purchase price $ 103,099 The fair values of the assets acquired and liabilities assumed are based on a preliminary estimate, which is subject to change within the measurement period. Given the timing of the acquisition, the Company utilized a benchmarking approach based on the Company’s prior acquisitions and similar industry acquisitions to determine the preliminary fair values for property and equipment and identified intangible assets. Upon completion of the final fair value assessment, the fair values of the assets acquired, liabilities assumed and resulting goodwill may differ materially from the preliminary assessment. Any changes to the initial estimates of the fair value of the assets acquired and liabilities assumed will be recorded to those assets and liabilities and residual amounts will be allocated to goodwill. Goodwill largely consists of expected growth synergies through the continued vertical integration of the Company within our Ingredients segment. Based on the preliminary valuation analysis, the identified intangible assets consist of customer relationships of $5,500, trade name of $2,000, acquired technology of $3,000 and permits of $500. The identified intangible assets are amortized using the straight-line method over their preliminary estimated useful lives of 15 years for customer relationships and acquired technology and 10 years for trade name and permits. Effective December 30, 2021, results from the operations of the soybean processing facility have been included in our consolidated statements of operations and comprehensive loss and incorporated in our Ingredients reporting unit and segment. Rose Acre Farms On September 17, 2021, we completed the acquisition of a soybean processing facility and related assets from Rose Acre Farms, Inc., an Indiana corporation (“Rose Acre Farms”), for cash consideration of $14,567 and entered into a long-term ground lease for the real estate upon which such soybean processing facility is located. The soybean processing facility will process the Company’s proprietary soybean varieties for distribution to end customers.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Assets and liabilities recorded at fair value on a recurring basis on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows Level 1 — Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 — Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Our financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, commodity derivatives, commodity contracts, accounts payable, accrued liabilities, warrant liabilities, conversion option liabilities, and notes payable. As of June 30, 2022 and December 31, 2021, we had cash and cash equivalents of $46,772 and $78,963, respectively, which includes money market funds with maturities of less than three months. At June 30, 2022 and December 31, 2021, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximated their fair value due to their short maturities. The following tables provide the financial instruments measured at fair value on a recurring basis based on the fair value hierarchy: June 30, 2022 Level 1 Level 2 Level 3 Total Assets U.S. treasury securities $ 19,166 $ — $ — $ 19,166 Corporate bonds — 122,345 — 122,345 Preferred stock — 21,624 — 21,624 Marketable securities $ 19,166 $ 143,969 $ — $ 163,135 Liabilities Warrant liabilities $ 4,729 $ — $ 28,128 $ 32,857 Conversion option liability — — 10,940 10,940 Total liabilities $ 4,729 $ — $ 39,068 $ 43,797 December 31, 2021 Level 1 Level 2 Level 3 Total Assets U.S. treasury securities $ — $ — $ — $ — Corporate bonds — 82,086 — 82,086 Preferred stock — 21,603 — 21,603 Marketable securities $ — $ 103,689 $ — $ 103,689 Liabilities Warrant liabilities $ 12,377 $ — $ 33,674 $ 46,051 Conversion option liability — — 8,783 8,783 Total liabilities $ 12,377 $ — $ 42,457 $ 54,834 There were no transfers of financial assets or liabilities into or out of Level 1, Level 2, or Level 3 for 2022 or 2021. All of the Company’s derivative contracts are centrally cleared and therefore are cash-settled on a daily basis. This results in the derivative contracts having a fair value that approximates zero on a daily basis. Therefore, there are no derivative assets or liabilities included in the table above. Refer to Note 6 for further discussion. The Company acquired commodity purchase and sales contracts in the acquisition of ZFS Creston, which were recorded at their estimated fair value. As outlined in Note 2, the Company designates all commodity purchase and sales contracts as normal purchases and normal sales and as a result do not account for them as derivatives under ASC 815. As of December 31, 2021 the Company had a contract asset of $2,354 and a contract liability of $2,652. The contract asset and liability is excluded from the table above as the contracts will not be measured at fair value on a recurring basis. Contract fair values were based upon forward commodity prices as of the date of acquisition, which fall into Level 2 in the fair value hierarchy. The contract asset and liability will be amortized as the remaining volume of the commodity purchase and sales contracts is physically settled. The warrant liabilities consist of PIPE Investment Warrants, Convertible Notes Payable Warrants, Notes Payable Warrants, Private Placement Warrants, and Public Warrants. The PIPE Investment Warrants are valued based on a Monte Carlo simulation that values the warrants using a probability weighted discounted cash flow model, which are considered Level 3 liabilities. The Convertible Notes Payable Warrants, Notes Payable Warrants and Private Placement Warrants are valued based on a Black-Scholes option pricing model, which are considered Level 3 liabilities. The Public Warrants are separately listed on the NYSE and traded under the symbol “BHIL WS” and are therefore considered Level 1 liabilities. Generally, increases or decreases in the fair value of the underlying common stock would result in a directionally similar impact in the fair value measurement of the associated Level 3 warrant liabilities. The following table summarizes the change in the warrant and conversion option liabilities categorized as Level 3 for the three and six months ended June 30, 2022 and 2021. Three Months Ended Six Months Ended Balance, beginning of period $ 45,169 $ 42,457 Change in estimated fair value (6,101) (29,993) Issuance of PIPE Investment warrants — 26,604 Ending balance, June 30, 2022 $ 39,068 $ 39,068 Three Months Ended Six Months Ended Balance, beginning of period $ 6,257 $ 5,241 Change in estimated fair value 1,703 2,719 Ending balance, June 30, 2021 $ 7,960 $ 7,960 Fair Value of Long-Term Debt As of June 30, 2022 and December 31, 2021, the fair value of the Company’s debt, including amounts classified as current, was $106,974 and $85,163, respectively. Fair values are based upon valuation models using market information, which fall into Level 3 in the fair value hierarchy.

Investments in Available-for-Sa

Investments in Available-for-Sale Securities	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Investments in Available-for-Sale Securities	Investments in Available-for-Sale SecuritiesThe Company has invested in marketable debt securities, primarily investment grade corporate bonds, preferred stock, and highly liquid U.S Treasury securities, which are held in the custody of a major financial institution. These securities are classified as available-for-sale and, accordingly, the unrealized gains and losses are recorded through other comprehensive income and loss. June 30, 2022 Cost Basis Gross Gross Fair Value U.S government and agency securities $ 19,191 $ — $ (26) $ 19,165 Corporate notes and bonds 127,952 52 (5,658) 122,346 Preferred stock 24,340 — (2,716) 21,624 Total Investments $ 171,483 $ 52 $ (8,400) $ 163,135 December 31, 2021 Cost Basis Gross Gross Fair Value U.S government and agency securities $ — $ — $ — $ — Corporate notes and bonds 82,007 572 (493) 82,086 Preferred stock 21,553 126 (76) 21,603 Total Investments $ 103,560 $ 698 $ (569) $ 103,689 The aggregate fair value of investments with unrealized losses that had been owned for less than a year was $146,997 and $48,098 at June 30, 2022 and December 31, 2021, respectively. The Company had no unrealized losses on investments owned for more than one year at June 30, 2022 and December 31, 2021, respectively. Available-for-sale investments outstanding as of June 30, 2022, classified as marketable securities in the consolidated balance sheets, have maturity dates ranging from the third quarter of 2022 through the fourth quarter of 2026. The fair value of marketable securities as of June 30, 2022 with maturities within one year and one to five years is $75,118 and $88,017, respectively. The Company classifies available-for-sale investments as current based on the nature of the investments and their availability to provide cash for use in current operations, if needed. In accordance with ASC 326, the Company reviews its portfolio of available-for-sale debt securities in an unrealized loss position quarterly to determine whether the decline in fair value has resulted from credit losses or other factors. This includes considering the extent to which the fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the Company compares the present value of the cash flows expected to be collected against the amortized cost basis. A credit loss is recorded if the present value of the cash flows is less than the amortized cost basis, limited by the amount that the fair value is less than the amortized cost basis. As of June 30, 2022, the Company determined that the unrealized losses were a result of market and other factors, including rising interest rates, rather than the result of credit losses and therefore no allowance for credit loss was recorded.

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives Corporate Risk Management Activities The Company uses exchange-traded futures to manage price risk of fluctuating Chicago Board of Trade (“CBOT”) prices related to forecasted purchases and sales of soybean and soybean-related products in the normal course of business. These risk management activities are actively monitored for compliance with the Company’s risk management policies. As of June 30, 2022, the Company held financial futures related to a portion of its forecasted purchases of soybeans for an aggregate notional volume of 6,025 bushels of soybeans; 4,345 bushels of the aggregate notional volume will settle in 2022 with the remaining 1,680 bushels settling in 2023. As of June 30, 2022, the Company held financial futures related to a portion of its forecasted sales of soybean oil for an aggregate notional volume of 563 pounds of soybean oil, all of which will settle in 2022. As of June 30, 2022, the Company held financial futures related to a portion of its forecasted sales of soybean meal for an aggregate notional volume of 103 tons of soybean meal, all of which will settle in 2022. Tabular Derivatives Disclosures The Company has master netting agreements with its counterparties, which allow for the settlement of contracts in an asset position with contracts in a liability position in the event of default or termination. Such netting arrangements reduce the Company’s credit exposure related to these counterparties. As all of the Company’s derivative contracts are centrally cleared and therefore are cash-settled on a daily basis, the fair value approximates zero. The Company’s derivative contracts as of June 30, 2022 were as follows: Asset Derivative Liability Derivative Soybeans $ 3,019 $ 1,839 Soybean oil 2,208 1,998 Soybean meal 1,162 1,619 Effect of daily cash settlement (6,389) (5,456) Net derivatives as classified in the balance sheet $ — $ — The Company’s derivative contracts as of December 31, 2021 were as follows: Asset Derivative Liability Derivative Soybeans $ 18 $ 48 Soybean oil 5 1 Soybean meal — 1,228 Effect of daily cash settlement (23) (1,277) Net derivatives as classified in the balance sheet $ — $ — The Company had a current asset representing excess cash collateral posted to a margin account of $3,568 and $2,504 as of June 30, 2022 and December 31, 2021, respectively. These amounts are not included with the derivatives presented in the table above and are included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Currently, the Company does not seek cash flow hedge accounting treatment for its derivative financial instruments and thus changes in fair value are reflected in current earnings. The tables below show the amounts of pre-tax gains and losses related to the Company’s derivatives: Three Months Ended June 30, 2022 2021 Revenues Cost of sales Revenues Cost of sales Consolidated statement of operations $ 110,747 $ (105,171) $ 39,692 $ (39,722) Soybeans — 327 — (263) Soybean oil (775) — 316 — Soybean meal 1,303 — — — Total gain (loss) recognized in income $ 528 $ 327 $ 316 $ (263) Six Months Ended June 30, 2022 2021 Revenues Cost of sales Revenues Cost of sales Consolidated statement of operations $ 203,192 $ (202,838) $ 71,494 $ (70,955) Soybeans — (5,020) — (1,368) Soybean oil (7,198) — 856 — Soybean meal 527 — — — Total (loss) gain recognized in income $ (6,671) $ (5,020) $ 856 $ (1,368) The Company’s soybean positions are designed to hedge risk related to inventory purchases, therefore the gains and losses on soybean instruments are recorded in cost of sales in the accompanying condensed consolidated statements of operations. The Company’s soybean oil and soybean meal positions are designed to hedge risk related to sales transactions therefore the gains and losses on soybean oil and soybean meal instruments are recorded in revenues in the accompanying condensed consolidated statements of operations. The Company classifies the cash effects of its derivatives within the “Cash Flows From Operating Activities” section of the condensed consolidated statements of cash flows.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: June 30, December 31, Raw materials and supplies $ 18,433 $ 20,578 Work-in-process 7,392 11,580 Finished goods 21,941 16,566 Total inventories $ 47,766 $ 48,724 Work-in-process inventory consists of seed provided to contracted seed producers and growers with which we hold a purchase option for, or are required to purchase, the future harvested seeds or grain as well as crops under production, which represents the direct costs of land preparation, seed, planting, growing, and maintenance.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Components of property and equipment are as follows: June 30, December 31, Land $ 8,026 $ 8,026 Furniture and fixtures 3,642 3,116 Machinery, field, and laboratory equipment 81,528 81,119 Computer equipment 2,641 2,545 Vehicles 3,112 2,660 Buildings and building improvements 25,882 26,911 Construction in progress 21,370 18,158 146,201 142,535 Less accumulated depreciation (21,439) (15,650) Property and equipment, net $ 124,762 $ 126,885 Depreciation expense was $3,361 and $2,839 for the three months ended June 30, 2022 and 2021, respectively. Depreciation expense was $6,643 and $3,564 for the six months ended June 30, 2022 and 2021, respectively. The Company capitalized $385 and $516 of interest costs during the three months ended June 30, 2022 and 2021, respectively. The Company capitalized $782 and $771 of interest costs during the six months ended June 30, 2022 and 2021, respectively. The Company conducted a review of its assets as of June 30, 2022 and determined that the carrying value of its assets are recoverable and no impairment charge was necessary. However, the Company is currently exploring strategic options for its Fresh operating segment which may result in the Company being unable to recover all or a portion of the carrying value of the segment’s assets. Fresh segment assets at risk of impairment as of June 30, 2022 had an aggregate carrying value of $40,410.

Other Current Assets

Other Current Assets	6 Months Ended
	Jun. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	Other Current Assets Prepaid expenses and other current assets consist of the following: June 30, December 31, Prepaid expenses $ 7,142 $ 9,325 Contract asset 1,973 2,588 Derivative margin asset 3,568 3,273 Tax receivable 913 2,254 Deposits 617 650 Commitment asset — 416 Other 331 1,747 $ 14,544 $ 20,253

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following: June 30, December 31, Payroll and employee benefits $ 7,941 $ 9,144 Insurance premiums 657 4,099 Professional services 1,619 2,517 Research and development 1,282 1,043 Inventory 10,013 3,168 Interest 124 178 PIPE Investment transaction costs 178 — Contract liability 1,065 2,652 Other 4,544 3,970 $ 27,423 $ 26,771

Debt

Debt	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Debt	Debt June 30, December 31, DDB Term loan, due April 2024 $ 7,962 $ 8,531 DDB Equipment loan, due July 2024 1,575 1,925 Convertible Notes Payable, due January 2025 102,518 80,000 Creston Note Payable, due August 2022 1,667 5,000 Equipment Financing, due March 2025 3,781 — Notes payable, varying maturities through June 2026 493 313 DDB Revolver 755 47 Less: unamortized debt discount and debt issuance costs (8,762) (11,665) 109,989 84,151 Less: DDB Revolver (755) (47) Less: current maturities of long-term debt (25,776) (6,934) Long-term debt $ 83,458 $ 77,170 Term Loan, Equipment Loan and Revolver In April 2019, our wholly owned subsidiary, Dakota Dry Bean, Inc. (“DDB”) entered into a credit agreement comprised of a $14,000 aggregate principal amount of floating rate, five-year term loan (“DDB Term Loan”), a $3,500 floating rate, five The DDB Credit Agreement is secured by substantially all the real and personal property of DDB and is guaranteed, in part, by Benson Hill, the parent company, to a maximum of $7,000. The DDB Term Loan is payable in equal quarterly installments of $284 plus interest with the remaining balance of $5,972 due in April 2024. The DDB Equipment Loan is payable in equal quarterly installments of $175 plus interest through July 2024. The interest rate on the DDB Term Loan and DDB Equipment Loan is equal to U.S. prime rate plus 0.75%, or 5.50% at June 30, 2022. The interest rate on the DDB Revolver is equal to U.S. prime rate plus 0.25%, or 5.00% at June 30, 2022. Under the Credit Agreement, DDB and the Company must comply with certain financial covenants based on DDB’s operations, including a minimum working capital covenant, a minimum net worth covenant, a funded debt-to-EBITDA ratio covenant, and a fixed charge coverage ratio covenant. Benson Hill as guarantor must also comply with a minimum cash covenant. The DDB Credit Agreement also contains various restrictions on our activities, including restrictions on indebtedness, liens, investments, distributions, acquisitions and dispositions, control changes, transactions with affiliates, establishment of bank and brokerage accounts, sale-leaseback transactions, margin stocks, hazardous substances, hedging, and management agreements. During the first quarter of 2021, we were in violation of certain financial covenants under the Credit Agreement, which were subsequently waived by the lender. In the first quarter of 2021, the DDB Credit Agreement was amended to clarify the definitions of net worth and EBITDA as used in the calculations of certain financial covenants. In the second quarter of 2021, the Credit Agreement was further amended to adjust the non-financial covenants. In the fourth quarter of 2021, the Revolver maturity date was extended to November 2022. While the Company is currently in compliance with the amended covenants, there is a risk that the Company will not maintain compliance with the covenants, as discussed further in Note 1. Convertible Notes Payable In December 2021, the Company entered into a financing agreement with an investment firm, which included a commitment by the lender to make term loans available to the Company in an amount of up to $100,000 with $80,000 available immediately and a second tranche of $20,000 available between April 2022 and June 2022 upon the Company’s achievement of the following milestones: (i) at least 85% of the Company’s projected revenue for the three months ending March 31, 2022; (ii) gross margin for the three months ending March 31, 2022 greater than (1.5)%; and (iii) an average public market capitalization of at least $650 million during the trailing 30 days prior to the date the lender makes the second tranche loan (together the “Convertible Loan and Security Agreement”). The Company executed term notes with the lender in December 2021 in the aggregate amount of $80,000 with an initial term of 36 months payable in interest only, at the greater of (a) the prime rate of interest as published in the Wall Street Journal or 3.25% per annum, plus (b) 5.75% per annum for the first 12 months and principal and interest payments for the remaining 24 months. The term notes are secured by substantially all of the Company’s assets. In June 2022, the Company amended the Convertible Loan and Security Agreement, which changed the definition of gross margin, the Conversion Price and the Exercise Price. The amendment to the definition of gross margin removed the impact of derivative hedging gains or losses related to future periods and resulted in the Company’s achievement of the milestones required to draw on the second tranche. The Company drew on the full amount of the second tranche, $20,000. The Company will make interest only payments in the average amount of $870 for the remaining seven months of the interest-only period and principal and interest payments in the average amount of $4,591 for the remaining 24 months. The interest-only period may be extended from 12 to 24 months upon the Company’s full draw of the second tranche of $20,000 and achievement of certain milestones based on the Company’s market capitalization and financial performance for the nine months ending September 30, 2022. Additionally, the term of the term notes may be extended from 36 to 42 months upon the Company’s achievement of certain milestones based on the Company’s market capitalization and financial performance for the nine months ending September 30, 2022 and compliance with all debt covenants. Upon maturity or other satisfaction of the term notes, a final payment (in addition to other payments of principal and interest) equal to $10,700 is payable by the Company to the lenders, however in the event all or any part of any term notes are outstanding when a change of control as defined in the Convertible Loan and Security Agreement occurs, the required final payment is $14,200. In the event the term notes are prepaid, a prepayment fee is due, ranging from 1% to 6% of the principal amount of the term notes, based upon the time from the initial closing to the prepayment date. At any time after six months and before 42 months from the closing date of the initial term loans, up to $20,000 of the principal amount of the term loans then outstanding may be converted (at the lender’s option) into shares of the Company’s common stock at a price per share (“Conversion Price”) equal to the lower of (a) $2.47; (b) in the case of any “equity purchase commitments” and/or “at-the-market” or similar transactions, which result in the realization by the Company of gross proceeds of $20,000 or more over any period of 14 consecutive trading days prior to September 30, 2022, the VWAP of the common stock on the last trading day of such 14 day period; or (c) the effective price per share of any bona fide equity offering, which closes after June 30, 2022 and prior to September 30, 2022. The conversion option is subject to: (a) the closing sales price of the Company’s common stock for each of the seven consecutive trading days immediately preceding the conversion, being greater than or equal to the conversion price; (b) the shares of the Company’s common stock issued in connection with any such conversion not exceeding 20% of the total trading volume of the Company’s common stock for the 22 consecutive trading days immediately prior to and including the effective date of the conversion; and (c) all lenders’ pro forma shares of the Company’s common stock resulting from the conversion option, when added to all lenders’ pro forma shares of the Company’s common stock resulting from the exercise of the warrants (as outlined in Note 12), not exceeding 2.5% of the number of shares of the Company’s common stock outstanding at the time of the conversion. As of the date of this report, the lender has not yet exercised their conversion option for any portion of the outstanding principal. The fair value of the conversion option, estimated at $8,783 at issuance, was recorded as a debt discount, which is amortized over the life of the term notes using the effective interest method and recorded as interest expense. Under the terms of the Convertible Loan and Security Agreement, we must comply with certain affirmative, negative, and financial covenants. These covenants are primarily restrictions on our activities, including restrictions on indebtedness, liens, dividends, and significant business changes. as well as a requirement to maintain at all times required minimum liquidity equal to or greater than six months. We were in compliance with these covenants in 2021 and year-to-date 2022. Creston Note Payable In connection with the acquisition of ZFS Creston in December 2021, the Company entered into a note payable with Zeeland Farm Services, Inc., a Michigan corporation, in the amount of $5,000 (the “Creston Note Payable”). The Creston Note Payable is payable in monthly installments equal to the greater of the reduction in the inventory value at ZFS Creston in the preceding month or $833 plus interest at 3% per annum from March 2022 to August 2022. Equipment Financing

Warrant Liabilities

Warrant Liabilities	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Warrants Liabilities	Warrant Liabilities Notes Payable Warrants In February 2020, in connection with the issuance of notes payable with an original principal amount of $20,000, along with a commitment to extend an additional $15,000 upon the achievement of certain financial conditions, the Company issued 1,077 warrants to purchase Series C-1 preferred shares or any subsequent preferred share round of Benson Hill Preferred Stock. The preferred stock warrant remained outstanding at the close of the Merger and, therefore, converted into a New Benson Hill Warrant without any action on the part of the Company or the warrant holder. Each warrant was converted based on the Exchange Ratio of 1.0754 resulting in 1,158 warrants to purchase New Benson Hill Common Stock outstanding at June 30, 2022 at an adjusted stock purchase price of $3.43. The fair value of the warrants attributable to the funds loaned to the Company, estimated at $3,332 at issuance, were recorded as a debt discount, which was amortized over the life of the term notes using the effective interest method and recorded as interest expense. The fair value of the warrants attributable to the commitment to fund the second tranche, estimated at $1,248 at issuance, were recorded as a current asset and amortized through the date of commitment expiration (December 2020) using the straight-line method and recorded as interest expense. The warrants are exercisable at the warrant holder’s discretion at any time before the expiration date of December 2035. If the New Benson Hill Warrant is held to expiration or if a change of control occurs, the warrants shall automatically exercise at no cost to the holder. Should the Company consummate a bridge financing prior to a change of control, the holders of the warrants may surrender their warrants to the Company and receive in exchange all of the same consideration, securities, instruments and rights as if the holder participated in the bridge financing with a loan in an amount equal to the shares issuable upon exercise of the warrants multiplied by the stock purchase price. In September 2021, and in connection with the issuance of Notes Payable with an original principal amount of $20,000 and a commitment to extend an additional $20,000, the Company issued warrants to purchase common stock, Series D preferred shares, or any subsequent preferred share round of Benson Hill. The fair value of the warrants attributable to the funds loaned to the Company, estimated at $3,523 at issuance, were recorded as a debt discount, which was amortized over the life of the term notes using the effective interest method and recorded as interest expense. The fair value of the warrants attributable to the remaining commitment (December 2021), estimated at $1,028 issuance, were recorded as a current asset and amortized through the date of commitment expiration using the straight-line method and recorded as interest expense. The option to draw down on the remaining commitment of $20,000 was terminated upon extinguishment of the note as outlined above. Immediately prior to the closing of the Merger with STPC on September 29, 2021, which qualified as a Liquidity Event, the warrant was automatically exchanged for 325 shares of Legacy Benson Hill Common Stock at no cost to the holder and a stock purchase warrant for 225 shares of the Company’s common stock was issued to the holder at an exercise price of $10.00. The Legacy Benson Hill Common Stock issued was converted at the Exchange Ratio resulting in 350 shares of New Benson Hill Common Stock and the stock purchase warrant was converted at the Exchange Ratio resulting in 242 warrants to purchase New Benson Hill Common Stock at an adjusted stock purchase price of $9.30. The stock purchase warrant was determined to be equity classified in accordance with U.S. GAAP and was outstanding at June 30, 2022. In September 2021 the Company repaid all amounts outstanding on the notes payable associated with these warrants. In conjunction with this repayment, the Company expensed the remaining unamortized debt discounts, commitment assets and debt issuance costs associated with these warrants. Convertible Notes Payable Warrants In December 2021 and in connection with the issuance of Convertible Notes Payable with an original principal amount of $80,000 along with a commitment to extend an additional $20,000 upon the achievement of certain milestones (see Note 11 — Debt ), the Company issued warrants exercisable or exchangeable for up to such aggregate number of shares of the Company’s common stock determined by dividing $3.0 million by the Exercise Price (as defined below). The warrants remained outstanding as of June 30, 2022. The per share exercise price of the warrants (the “Exercise Price”) will equal the lower of (a) $2.47; (b) in the case of any “equity purchase commitments” and/or “at-the-market” or similar transactions, which result in the realization by the Company of gross proceeds of $20.0 million or more over any period of 14 consecutive trading days prior to September 30, 2022, the VWAP of the common stock on the last trading day of such 14 day period; or (c) the effective price per share of any bona fide equity offering, which closes after June 30, 2022 and prior to September 30, 2022. The fair value of the warrants attributable to the funds loaned to the Company, estimated at $1,690 at issuance, was recorded as a debt discount, which is amortized over the life of the convertible term notes using the effective interest method and recorded as interest expense. The fair value of the warrants attributable to the commitment to fund the second tranche, estimated at $423 at issuance, was recorded as a current asset and will be amortized through the date of commitment expiration (June 2022) using the straight-line method and recorded as interest expense. The warrants are exercisable at the warrant holder’s discretion at any time before the expiration date of December 2026. Upon a change in control, the warrants would be automatically exchanged for shares of the Company’s common stock at no cost to the holder. PIPE Investment Warrants In March 2022, the Company entered into definitive subscription agreements with certain investors providing for the private placement of an aggregate of 26,150 units at a price of $3.25 per unit (“PIPE Investment”), for an aggregate purchase price of $85.0 million. Each unit consists of (i) one share of the Company’s common stock, par value $0.0001 per share, and (ii) a warrant to purchase one-third of one share of common stock for a total of 8,716 warrants. In connection with the private placement, the Company incurred transactions costs of $4,161, $705 of which was allocated to the warrants and expensed. As of June 30, 2022, $362 of the transaction costs were unpaid. The 8,716 warrants remained outstanding as of June 30, 2022. Each warrant to purchase common stock has an exercise price of $3.90 per share and may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed a specified threshold set forth therein, subject to increase to up to 19.99% at the option of the holder. Each warrant is redeemable by the Company for $0.10 if the closing price of the Company’s common stock exceeds $9.75 per share for any 20 trading days within a 30-trading day period. The warrants are exercisable at the warrant holder’s discretion at any time before the expiration date of March 2027. Public and Private Placement Warrants On January 8, 2021, Star Peak Corp II consummated its IPO of 40,250 units. Each unit consists of one share of Class A common stock and one-fourth of one Public Warrant, for a total of 10,063 Public Warrants. Simultaneously with the closing of STPC’s IPO, STPC consummated the private placement of 6,553 Private Placement Warrants. Upon the completion of the Merger, the Company assumed each of these warrants, which remain outstanding in whole at June 30, 2022. Public Warrants may only be exercised for a whole number of shares of common stock. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants are publicly traded under the ticker BHIL WS. The Public Warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination (September 2026) or earlier upon redemption or liquidation. The Public Warrants became exercisable on January 8, 2022. The Private Placement Warrants are identical to the Public Warrants, except the Private Placement Warrants will be non-redeemable so long as they are held by Star Peak Sponsor II LLC (“the Sponsor”) or its permitted transferees. If the Private Placement Warrants are held by someone other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. Redemption of Public Warrants and Private Placement Warrants when the price per share of common stock equals or exceeds $18.00: The Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): in whole and not in part; at a price of $0.01 per warrant; upon a minimum of 30 days’ prior written notice of redemption; and if, and only if, the last reported sale price (the “closing price”) of common stock equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. The Company will not redeem the warrants as described above unless a current prospectus relating to those shares of common stock is available throughout the 30-day redemption period. Any such exercise would not be on a “cashless” basis and would require the exercising holder to pay the exercise price for each warrant being exercised. Redemption of Public Warrants and Private Placement Warrants when the price per share of common stock equals or exceeds $10.00: The Company may redeem the outstanding warrants: in whole and not in part; at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption, provided that holders will be able to exercise their warrants, but only on a cashless basis, prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the “fair market value” of common stock; if, and only if, the closing price of the common stock equals or exceeds $10.00 per Public Share (as adjusted) for any 20 trading days within the 30-trading day period ending three

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe Company’s effective tax rate was 0% for the three and six month periods ended June 30, 2022, and 2021, respectively. The 2022 and 2021 effective tax rates differed from the statutory rate of 21% primarily due to the fact that the Company recorded no income tax benefit on the Company’s pretax losses as the Company recorded a full valuation allowance globally. The tax expense recorded relates to minor foreign deferred tax liabilities and the impacts of tax amortization of indefinite-lived intangibles.

Comprehensive Income

Comprehensive Income	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Comprehensive Income	Comprehensive IncomeThe Company’s other comprehensive income (loss) (“OCI”) consists of foreign currency translation adjustments from its Brazil subsidiary, which does not use the U.S. dollar as its functional currency, and unrealized gains and losses on marketable debt securities classified as available for sale. The following table shows changes in accumulated other comprehensive income (“AOCI”) by component for the three and six months ended June 30, 2022 and 2021: Cumulative Foreign Currency Translation Unrealized Gains/(Losses) on Marketable Securities Total Balance at March 31, 2022 $ (441) $ (3,286) $ (3,727) Other comprehensive income (loss) before reclassifications 20 (4,393) (4,373) Amounts reclassified from AOCI — 1,022 1,022 Other comprehensive income 20 (3,371) (3,351) Balance at June 30, 2022 $ (421) $ (6,657) $ (7,078) Balance at December 31, 2021 $ (376) $ (727) $ (1,103) Other comprehensive income before reclassifications (45) (8,159) (8,204) Amounts reclassified from AOCI — 2,229 2,229 Other comprehensive income (loss) (45) (5,930) (5,975) Balance at June 30, 2022 $ (421) $ (6,657) $ (7,078) Balance at March 31, 2021 $ (451) $ (79) $ (530) Other comprehensive loss before reclassifications 70 358 428 Amounts reclassified from AOCI — (300) (300) Other comprehensive loss 70 58 128 Balance at June 30, 2021 $ (381) $ (21) $ (402) Balance at December 31, 2020 $ (380) $ 55 $ (325) Other comprehensive loss before reclassifications (1) 271 270 Amounts reclassified from AOCI — (347) (347) Other comprehensive loss (1) (76) (77) Balance at June 30, 2021 $ (381) $ (21) $ (402) Amounts reclassified from AOCI were reported within “Other (income) expense, net” on the condensed consolidated statement of operations. The Company’s accounting policy is to release the income tax effects (if applicable) from AOCI when the individual units of account are sold.

Loss Per Common Share

Loss Per Common Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Loss Per Common Share	Loss Per Common ShareThe Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted average number of common shares and the effect of potentially dilutive securities outstanding during the period. Potentially dilutive securities may consist of stock warrants, stock options and restricted stock units. The dilutive effect of outstanding stock warrants, stock options and restricted stock units are reflected in diluted earnings per share by application of the treasury stock method. The weighted average share impact of stock warrants, stock options, and restricted stock units that were excluded from the calculation of diluted shares outstanding due to the Company incurring a net loss for the three and six month periods ending June 30, 2022 and 2021 were as follows: Three Months Six Months Ended Anti-dilutive common share equivalents: 2022 2021 2022 2021 Warrants — 567 83 285 Stock options 3,813 7,369 4,266 5,676 Restricted stock units 5,285 — 4,102 — Total anti-dilutive common share equivalents 9,098 7,936 8,451 5,961 The following table provides the basis for basic and diluted EPS by outlining the numerators and denominators of the computations: Three Months Six Months Ended 2022 2021 2022 2021 Numerator: Net loss $ (27,554) $ (27,419) $ (44,130) $ (49,766) Denominator: Weighted average common shares outstanding, basic and diluted 185,530 109,222 173,189 108,989 Net loss per common share, basic and diluted $ (0.15) $ (0.25) $ (0.25) $ (0.46)

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation On June 12, 2012, the shareholders of Legacy Benson Hill approved the 2012 Equity Incentive Plan (the “2012 Plan”), which has been subsequently amended. The 2012 Plan provides for the issuance of up to 17,464 equity-based awards in the form of restricted common stock or stock options awards to eligible employees, directors, and consultants. On September 29, 2021, the Company’s stockholders approved the 2021 Omnibus Incentive Plan, (the “Plan”), replacing the 2012 Plan, pursuant to which the Company’s Board of Directors (the “Board”) may grant stock awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards, to officers, employees, and directors. The Plan allows for non-employee director grants, which are accounted for in the same manner as employee awards. The Plan provides for the issuance of up to 16,502 stock awards as of June 30, 2022. Stock Options Under the 2012 Plan, the Company granted stock options which typically vest over two years for directors and non-employee directors and four years for all other grants, all with a contractual life of ten years. The exercise price of stock options issued under the 2012 Plan were set at the fair market value of such shares on the date of grant. The grant date fair value for the Company’s stock options granted under the 2012 Plan in the six months ended June 30, 2021 were based on the following assumptions used within the Black-Scholes option pricing model: 2021 Expected dividend yield 0 % Expected volatility 63 % Risk-free interest rate 0.7 % Expected term in years 6.1 years Weighted average grant date fair value $ 1.54 At June 30, 2022 and 2021 the Company had 4,514 and 8,958 non-vested options under the 2012 Plan, respectively. There are 10,317 registered shares of common stock reserved for issuance upon exercise or settlement, as applicable, of awards made under the 2012 Plan. While no further awards may be granted under the 2012 Plan, the plan continues to govern all outstanding awards previously issued under it. Restricted Stock Units The Company’s restricted stock units (“RSUs”) are convertible into shares of the Company’s common stock upon vesting on a one-to-one basis. As of June 30, 2022, the Company had 5,211 RSUs outstanding, subject to only time-based vesting conditions, and 4,424 RSUs outstanding, subject to time-based and market-based performance vesting conditions. Any unvested portion of the RSUs shall be terminated and forfeited upon termination of employment or service of the grantee or the failure to achieve market-based performance vesting conditions within the award term. As of June 30, 2022, 1,431 of the market-based performance awards were subject to the following vesting conditions (the “Earnout Awards”): (i) 50% of the Earnout Awards will vest if the closing price of the Company’s publicly traded common stock is greater than or equal to $14.00 over any 20 trading days within any 30 consecutive trading day period within 36 months following the closing of the Merger and (ii) 50% of the Earnout Awards will vest if the closing price of the Company’s publicly traded common stock is greater than or equal to $16.00 over any 20 trading days within any 30 consecutive trading day period within 36 months following the closing of the Merger. Any portion of the Earnout Awards that have not vested as of the third anniversary of the closing of the Merger will be forfeited. Additionally, the vesting of the Earnout Awards is subject to the award recipient’s continued service to the Company through the applicable vesting date. Therefore, should the award recipient’s service terminate prior to the vesting of an Earnout Award, the recipient’s Earnout Awards will be forfeited. As of June 30, 2022, 993 of the market-based performance awards were subject to the following vesting conditions (the “Executive Founders Grants”): (i) 50% of the Executive Founders Grants will performance vest if the 30-day VWAP of the Company’s publicly traded common stock is greater than or equal to $15.00 after September 29, 2022 but on or prior to September 29, 2024 and (ii) 50% of the Executive Founders Grants will performance vest if the 30-day VWAP of the Company’s publicly traded common stock is greater than or equal to $20.00 after September 29, 2022 but on or prior to September 29, 2026. If the $15.00 VWAP target is not achieved on or prior to September 29, 2024, the target will be increased by 10% to $16.50 and be eligible to performance vest on or prior to September 29, 2025. The Executive Founders Grants will become 100% time vested on September 29, 2024. Any performance vested portion of the Executive Founders Grants that has not time vested will remain outstanding. Any portion of the Executive Founders Grants that has not met both time and performance conditions, and therefore vested as of September 29, 2026, will be forfeited. As of June 30, 2022, 2,000 of the market-based performance awards were subject to the following vesting conditions (the “CEO Founders Grant”): (i) 25% of the CEO Founders Grant will performance vest if the 30-day VWAP of the Company’s publicly traded common stock is greater than or equal to $15.00 after September 29, 2022 but on or prior to September 29, 2024, (ii) 25% of the CEO Founders Grant will performance vest if the 30-day VWAP of the Company’s publicly traded common stock is greater than or equal to $20.00 after September 29, 2022 but on or prior to September 29, 2025, (iii) 25% of the CEO Founders Grant will performance vest if the 30-day VWAP of the Company’s publicly traded common stock is greater than or equal to $25.00 after September 29, 2022 but on or prior to September 29, 2026, and (iv) 25% of the CEO Founders Grant will performance vest if the 30-day VWAP of the Company’s publicly traded common stock is greater than or equal to $30.00 after September 29, 2022 but on or prior to September 29, 2027. If any of the VWAP targets in the foregoing clauses (i)-(iv) are not achieved on or prior to the respective specified deadlines, such VWAP target will be increased by 10% and the applicable 25% tranche of the RSUs with respect to that VWAP target (as increased) will vest if and when such increased VWAP target is achieved at any time within the 12-month period following the original deadline for such VWAP target. The CEO Founders Grant will become 100% time vested on September 29, 2024. Any performance vested portion of the CEO Founders Grant that has not time vested will remain outstanding. Any portion of the CEO Founders Grant that has not met both time and performance conditions, and therefore vested as of September 29, 2028, will be forfeited. The closing price and 30-day VWAP thresholds of the Company’s common stock are considered market conditions under ASC 718 and are estimated on the grant date using a Monte Carlo simulation. Recognition of stock-based compensation expense of all vesting tranches commenced on the date of grant, as the probability of meeting the price thresholds are not considered in determining the timing of expense recognition. Key assumptions for estimating the market-based performance awards’ fair value at the date of grant included the closing price of the Company’s common stock on the grant date, historical volatilities of the common stock of comparable publicly traded companies, the risk free interest rate, and the grant term. The time-based awards’ fair value was determined based on the closing price of the Company’s common stock on the date of grant. Stock-Based Compensation Expense The Company recognized $5,676 and $11,359 of compensation expense related to stock option grants during the three and six months ended June 30, 2022, respectively. The Company recognized $709 and $1,356 of compensation expense related to stock option grants during the three and six months ended June 30, 2021, respectively.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation The Company accrues for costs related to contingencies when a loss is probable, and the amount is reasonably determinable. Disclosure of contingencies is included in the consolidated financial statements when it is at least reasonably possible that a material loss or an additional material loss in excess of amounts already accrued may be incurred. For all litigation matters, the Company accrued $0 as of June 30, 2022 and December 31, 2021. Other Commitments At June 30, 2022, the Company has committed to purchase from seed producers and growers at dates throughout 2022 and 2023 at fixed prices aggregating to $71.8 million based on commodity futures or market prices, other payments to growers, and estimated yields per acre. In addition to the obligations for which the price is fixed or determinable, the Company has committed to purchase from seed producers and growers 625 bushels throughout 2022 and 2023 for which the pricing is currently variable. These amounts are not recorded in the condensed consolidated financial statements because the Company has not taken delivery of the grain or seed as of June 30, 2022 and due to the fact that the grain or seed are subject to specified quality standards prior to delivery.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Information	Segment Information The Company’s reportable business segments reflect the manner in which its chief operating decision maker (“CODM”) allocates resources and assesses performance, which is at the operating segment level. The Ingredients reportable segment delivers more nutritious food ingredients derived from soybean seeds, meal and oil, and processed yellow peas. The Fresh reportable segment is a grower, packer and distributor of year-round fresh produce located in the southeastern United States. Financial results associated with licensing arrangements that are not allocated to the Fresh or Ingredients reportable segment and costs associated with centralized operations are reported as Unallocated and other. Centralized operations represent corporate and headquarter-related expenses, which include legal, finance, human resources, and other research and development and administrative expenses that are not allocated to the Fresh or Ingredients reportable segments. Our CODM reviews segment performance and allocates resources based upon segment revenue and Adjusted EBITDA. The Company defines Adjusted EBITDA as consolidated net loss before net interest expense, income tax provision and depreciation and amortization, further adjusted to exclude stock-based compensation, other income and expense, and the impact of significant non-recurring items. Adjusted EBITDA is a non-GAAP financial measure of performance. A reconciliation of the Company’s consolidated loss from continuing operations to Adjusted EBITDA is presented below. The Company had no intersegment revenues. Operating segment results for the three and six month periods ended June 30, 2022 and 2021 are presented below. Revenues Ingredients Fresh Unallocated and other Total Three Months Ended June 30, 2022 Domestic $ 91,144 $ 17,116 $ 86 $ 108,346 International 2,401 — — 2,401 Total $ 93,545 $ 17,116 $ 86 $ 110,747 Revenues Ingredients Fresh Unallocated and other Total Three Months Ended June 30, 2021 Domestic $ 22,724 $ 16,906 $ 62 $ 39,692 International — — — — Total $ 22,724 $ 16,906 $ 62 $ 39,692 Revenues Ingredients Fresh Unallocated and other Total Three Months Ended June 30, 2022 Point in time $ 93,545 $ 17,116 $ — $ 110,661 Over time — — 86 86 Total $ 93,545 $ 17,116 $ 86 $ 110,747 Revenues Ingredients Fresh Unallocated and other Total Three Months Ended June 30, 2021 Point in time $ 22,724 $ 16,906 $ 4 $ 39,634 Over time — — 58 58 Total $ 22,724 $ 16,906 $ 62 $ 39,692 Revenues Ingredients Fresh Unallocated and other Total Six Months Ended June 30, 2022 Domestic $ 155,565 $ 43,435 $ 139 $ 199,139 International 4,053 — — 4,053 Total $ 159,618 $ 43,435 $ 139 $ 203,192 Revenues Ingredients Fresh Unallocated and other Total Six Months Ended June 2021 Domestic $ 36,919 $ 34,470 $ 105 $ 71,494 International — — — — Total $ 36,919 $ 34,470 $ 105 $ 71,494 Revenues Ingredients Fresh Unallocated and other Total Six Months ended June 30, 2022 Point in time $ 159,618 $ 43,435 $ — $ 203,053 Over time — — 139 139 Total $ 159,618 $ 43,435 $ 139 $ 203,192 Revenues Ingredients Fresh Unallocated and other Total Six Months Ended June 30, 2021 Point in time $ 36,919 $ 34,470 $ 14 $ 71,403 Over time — — 91 91 Total $ 36,919 $ 34,470 $ 105 $ 71,494 Revenue Adjusted Three Months Ended June 30, 2022 Ingredients $ 93,545 $ (1,145) Fresh 17,116 (304) Unallocated and other 86 (14,217) Total segment results $ 110,747 $ (15,666) Adjustments to reconcile consolidated net loss to Adjusted EBITDA: Consolidated net loss $ (27,554) Interest expense, net 3,524 Income tax expense (benefit) 56 Depreciation and amortization 5,538 Stock-based compensation 5,676 Other expense (income), net 938 Change in fair value of warrants and conversion options (5,899) Other nonrecurring costs, including acquisition, transaction and integration costs 294 Non-recurring SOX readiness costs 70 Severance expense 124 Fresh segment crop failure costs 1,567 Total Adjusted EBITDA $ (15,666) Revenue Adjusted Three Months Ended June 30, 2021 Ingredients $ 22,724 $ (6,409) Fresh 16,906 165 Unallocated and other 62 (9,530) Total segment results $ 39,692 $ (15,774) Adjustments to reconcile consolidated net loss to Adjusted EBITDA: Consolidated net loss $ (27,419) Interest expense, net 1,277 Income tax (benefit) expense — Depreciation and amortization 2,839 Stock-based compensation 709 Other (income) expense, net (170) Change in fair value of warrants and conversion options 1,703 Other nonrecurring costs, including acquisition costs 527 South America seed production costs 2,805 Non-recurring public company readiness costs 1,955 Total Adjusted EBITDA $ (15,774) Revenue Adjusted Six Months Ended June 30, 2022 Ingredients $ 159,618 $ (16,040) Fresh 43,435 1,925 Unallocated and other 139 (29,083) Total segment results $ 203,192 $ (43,198) Adjustments to reconcile consolidated net loss to Adjusted EBITDA: Consolidated net loss $ (44,130) Interest expense, net 9,912 Income tax expense (benefit) 17 Depreciation and amortization 10,942 Stock-based compensation 11,359 Other expense (income), net 2,254 Change in fair value of warrants and conversion options (37,640) Other nonrecurring costs, including acquisition, transaction, and integration costs 312 Non-recurring SOX readiness costs 282 Severance expense 289 Fresh segment crop failure costs 1,567 PIPE Investment transaction costs 705 Fresh segment restructuring expenses 933 Total Adjusted EBITDA $ (43,198) Revenue Adjusted Six Months Ended June 30, 2021 Ingredients $ 36,919 $ (13,197) Fresh 34,470 (172) Unallocated and other 105 (17,252) Total segment results $ 71,494 $ (30,621) Adjustments to reconcile consolidated net loss to Adjusted EBITDA: Consolidated net loss $ (49,766) Depreciation and amortization 5,430 Stock-based compensation 1,356 Other (income) expense, net (388) Change in fair value of warrants and conversion options 2,719 Interest expense, net 2,535 Other nonrecurring items, including acquisition costs 527 South America seed production costs 2,805 Non-recurring public company readiness costs 4,161 Income tax expense (benefit) — Total Adjusted EBITDA $ (30,621) As the CODM does not evaluate the operating segments nor make decisions regarding the operating segments based on total assets, we have excluded this disclosure.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsWe consider events or transactions that occur after the balance sheet date but prior to the date the financial statements are available to be issued for potential recognition or disclosure in the financial statements. The Company has completed an evaluation of all subsequent events after the balance sheet date of June 30, 2022 through the date the accompanying financial statements were available to be issued, to ensure that these financial statements include appropriate disclosure of events both recognized in the financial statements as of June 30, 2022, and events that occurred subsequently but were not recognized in the financial statements. On July 21, 2022, the Company filed a Registration Statement on Form S-8 with the SEC to register 5,000 shares of common stock, par value $0.0001 per share, to be offered and sold under the Company’s 2022 Employee Stock Purchase Plan (the “Plan”). The Plan was adopted by the Board of Directors of the Company on April 20, 2022 and was approved by our stockholders at the Company’s Annual Meeting held on June 13, 2022. On August 5, 2022, the Company entered into an exclusive collaboration and marketing rights agreement (the “Collaboration Agreement”) with Archer-Daniels-Midland Company (“ADM”) to collaborate on an exclusive basis in the commercialization of certain high-protein soy ingredients for the human food and nutrition market in North America based on certain of the Company’s proprietary commercial soybean seed genetics (“Proprietary Soy Genetics”). Pursuant to the terms of the Collaboration Agreement, the Company will, among other things, collaborate with ADM to engage soybean growers in certain parts of the United States to source production and supply of grain grown from Proprietary Soy Genetics (“Proprietary Soy Grain”) for processing by ADM into soy protein ingredients. The Company will receive an upfront cash payment, annual technology access fees, and value sharing payments on all soy protein ingredients sold by ADM that are processed from the Proprietary Soy Grain supplied by the Company, and the Company is eligible to receive milestone payments upon achievement of certain objectives. Unless earlier terminated, the Collaboration Agreement will remain in effect until December 31, 2027, or until December 31, 2030 if extended pursuant to its terms. See the Current Report on Form 8-K filed with the SEC on August 8, 2022 for additional information.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Principles of Consolidation	The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial reporting and Securities and Exchange Commission regulations.
Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Prior to the Merger, the Company recorded shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company applied the guidance in ASC 480-10-S99-3A, Accounting for Redeemable Equity Instruments , and therefore classified all outstanding redeemable convertible preferred stock as temporary equity. The redeemable convertible preferred stock was recorded outside of stockholders’ equity because, in the event of certain deemed liquidation events considered not solely within the Company’s control, such as a merger, acquisition, and sale of all or substantially all of the Company’s assets, the preferred stock would become redeemable at the option of the holders. In the event of a change of control of the Company, proceeds received from the sale of such shares would be distributed in accordance with the liquidation preferences set forth in the Company’s Amended and Restated Certificate of Incorporation then in effect. All redeemable convertible preferred stock previously classified as temporary equity was retroactively adjusted and reclassified to permanent equity as a result of the Merger. As a result of the Merger, each share of Legacy Benson Hill Preferred Stock that was then issued and outstanding was automatically converted into Legacy Benson Hill Common Stock, such that each converted share of Legacy Benson Hill Preferred Stock was no longer outstanding and ceased to exist. Each share of Legacy Benson Hill Common Stock, including the Legacy Benson Hill Common Stock issued upon conversion of Legacy
Business Combinations	Business Combinations The Company allocates the purchase price of its acquisitions to the assets acquired and liabilities assumed based upon their respective fair values at the acquisition date. The Company utilizes management estimates and an independent third-party valuation firm to assist in determining these fair values. The excess of the acquisition price over the estimated fair value of the net assets acquired is recorded as goodwill. Goodwill is adjusted for any changes to acquisition date fair value amounts made within the measurement period. Acquisition-related transaction costs are recognized separately from the business combination and expensed as incurred.
Recently Adopted Accounting Guidance And Recently Issued Accounting Guidance Not Yet Effective	Recently Adopted Accounting Guidance In June 2016, the FASB issued ASU 2016-13, Financial Instruments  — Credit Losses (“ASU 2016-13” or “CECL”), which requires measurement and the recognition of expected credit losses for financial assets held. The standard requires the measurement of expected credit losses to be based on relevant information, including historical experience, current conditions and a forecast that is supportable. The Company adopted the standard in the first quarter of 2022, with minimal impact to our consolidated financial statements. As part of the adoption, the Company reviewed its’ portfolio of available-for-sale debt securities in an unrealized loss position, and assessed whether it intends to sell, or it is more likely than not that it will be required to sell before recovery of its’ amortized cost basis. Additionally, the Company evaluated whether the decline in fair value has resulted from credit losses or other factors by considering the extent to which the fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the Company compares the present value of the cash flows expected to be collected against the amortized cost basis. A credit loss is recorded if the present value of the cash flows is less than the amortized cost basis, limited by the amount that the fair value is less than the amortized cost basis. Upon adoption, the Company did not record an allowance for credit losses on its available-for-sale debt securities. Additionally, the Company reviewed its open trade receivables arising from contractual sales. As part of its analysis, the Company performs periodic credit reviews of all active customers, reviews all trade receivables greater than 90 days past due, calculates historical loss rates and reviews current payment trends of all customers. Recently Issued Accounting Guidance Not Yet Effective In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 applies only to contracts and hedging relationships that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued due to reference rate reform. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. We are currently evaluating our contracts and the optional expedients provided by the new standard. In August 2020, the FASB issued ASU 2020-06, Debt (“ASU 2020-06”). ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock. For convertible instruments with conversion features that are not required to be accounted for as derivatives under ASC 815, Derivatives and Hedging , or that do not result in substantial premiums accounted for as paid-in capital, the embedded conversion features no longer are separated from the host contract. The Company is currently evaluating the impact ASU 2020-06 will have on its condensed consolidated financial statements.

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Acquired Assets and Liabilities	The acquisition of the food-grade white flake and soy flour manufacturing facility was accounted for as a business combination, and accordingly, the acquired assets and liabilities were recorded at their preliminary estimated fair value, as presented below: Estimated Fair Value at Assets: Cash and cash equivalents $ 56 Accounts receivable 10,729 Inventories 18,209 Prepaid expenses and other current assets 3,627 Property and equipment 60,000 Right of use asset 853 Other assets 2,000 Identified intangible assets 11,000 Goodwill 7,079 Total assets acquired 113,553 Liabilities: Accounts payable 4,661 Lease liability 853 Accrued expenses and other liabilities 4,940 Total liabilities assumed 10,454 Total purchase price $ 103,099

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Financial Instruments Measured at Fair Value	The following tables provide the financial instruments measured at fair value on a recurring basis based on the fair value hierarchy: June 30, 2022 Level 1 Level 2 Level 3 Total Assets U.S. treasury securities $ 19,166 $ — $ — $ 19,166 Corporate bonds — 122,345 — 122,345 Preferred stock — 21,624 — 21,624 Marketable securities $ 19,166 $ 143,969 $ — $ 163,135 Liabilities Warrant liabilities $ 4,729 $ — $ 28,128 $ 32,857 Conversion option liability — — 10,940 10,940 Total liabilities $ 4,729 $ — $ 39,068 $ 43,797 December 31, 2021 Level 1 Level 2 Level 3 Total Assets U.S. treasury securities $ — $ — $ — $ — Corporate bonds — 82,086 — 82,086 Preferred stock — 21,603 — 21,603 Marketable securities $ — $ 103,689 $ — $ 103,689 Liabilities Warrant liabilities $ 12,377 $ — $ 33,674 $ 46,051 Conversion option liability — — 8,783 8,783 Total liabilities $ 12,377 $ — $ 42,457 $ 54,834
Summary of Change in Preferred Stock Warrant Liability Categorized as Level 3	The following table summarizes the change in the warrant and conversion option liabilities categorized as Level 3 for the three and six months ended June 30, 2022 and 2021. Three Months Ended Six Months Ended Balance, beginning of period $ 45,169 $ 42,457 Change in estimated fair value (6,101) (29,993) Issuance of PIPE Investment warrants — 26,604 Ending balance, June 30, 2022 $ 39,068 $ 39,068 Three Months Ended Six Months Ended Balance, beginning of period $ 6,257 $ 5,241 Change in estimated fair value 1,703 2,719 Ending balance, June 30, 2021 $ 7,960 $ 7,960

Investments in Available-for-_2

Investments in Available-for-Sale Securities (Tables)	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Summary of Securities Classified as Available-for-Sale	These securities are classified as available-for-sale and, accordingly, the unrealized gains and losses are recorded through other comprehensive income and loss. June 30, 2022 Cost Basis Gross Gross Fair Value U.S government and agency securities $ 19,191 $ — $ (26) $ 19,165 Corporate notes and bonds 127,952 52 (5,658) 122,346 Preferred stock 24,340 — (2,716) 21,624 Total Investments $ 171,483 $ 52 $ (8,400) $ 163,135 December 31, 2021 Cost Basis Gross Gross Fair Value U.S government and agency securities $ — $ — $ — $ — Corporate notes and bonds 82,007 572 (493) 82,086 Preferred stock 21,553 126 (76) 21,603 Total Investments $ 103,560 $ 698 $ (569) $ 103,689

Derivatives (Tables)

Derivatives (Tables)	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Contracts	The Company’s derivative contracts as of June 30, 2022 were as follows: Asset Derivative Liability Derivative Soybeans $ 3,019 $ 1,839 Soybean oil 2,208 1,998 Soybean meal 1,162 1,619 Effect of daily cash settlement (6,389) (5,456) Net derivatives as classified in the balance sheet $ — $ — The Company’s derivative contracts as of December 31, 2021 were as follows: Asset Derivative Liability Derivative Soybeans $ 18 $ 48 Soybean oil 5 1 Soybean meal — 1,228 Effect of daily cash settlement (23) (1,277) Net derivatives as classified in the balance sheet $ — $ —
Schedule of Pre-tax Gains (Losses)	The tables below show the amounts of pre-tax gains and losses related to the Company’s derivatives: Three Months Ended June 30, 2022 2021 Revenues Cost of sales Revenues Cost of sales Consolidated statement of operations $ 110,747 $ (105,171) $ 39,692 $ (39,722) Soybeans — 327 — (263) Soybean oil (775) — 316 — Soybean meal 1,303 — — — Total gain (loss) recognized in income $ 528 $ 327 $ 316 $ (263) Six Months Ended June 30, 2022 2021 Revenues Cost of sales Revenues Cost of sales Consolidated statement of operations $ 203,192 $ (202,838) $ 71,494 $ (70,955) Soybeans — (5,020) — (1,368) Soybean oil (7,198) — 856 — Soybean meal 527 — — — Total (loss) gain recognized in income $ (6,671) $ (5,020) $ 856 $ (1,368)

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following: June 30, December 31, Raw materials and supplies $ 18,433 $ 20,578 Work-in-process 7,392 11,580 Finished goods 21,941 16,566 Total inventories $ 47,766 $ 48,724

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Components of property and equipment are as follows: June 30, December 31, Land $ 8,026 $ 8,026 Furniture and fixtures 3,642 3,116 Machinery, field, and laboratory equipment 81,528 81,119 Computer equipment 2,641 2,545 Vehicles 3,112 2,660 Buildings and building improvements 25,882 26,911 Construction in progress 21,370 18,158 146,201 142,535 Less accumulated depreciation (21,439) (15,650) Property and equipment, net $ 124,762 $ 126,885

Other Current Assets (Tables)

Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Current Assets	Prepaid expenses and other current assets consist of the following: June 30, December 31, Prepaid expenses $ 7,142 $ 9,325 Contract asset 1,973 2,588 Derivative margin asset 3,568 3,273 Tax receivable 913 2,254 Deposits 617 650 Commitment asset — 416 Other 331 1,747 $ 14,544 $ 20,253

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: June 30, December 31, Payroll and employee benefits $ 7,941 $ 9,144 Insurance premiums 657 4,099 Professional services 1,619 2,517 Research and development 1,282 1,043 Inventory 10,013 3,168 Interest 124 178 PIPE Investment transaction costs 178 — Contract liability 1,065 2,652 Other 4,544 3,970 $ 27,423 $ 26,771

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt	June 30, December 31, DDB Term loan, due April 2024 $ 7,962 $ 8,531 DDB Equipment loan, due July 2024 1,575 1,925 Convertible Notes Payable, due January 2025 102,518 80,000 Creston Note Payable, due August 2022 1,667 5,000 Equipment Financing, due March 2025 3,781 — Notes payable, varying maturities through June 2026 493 313 DDB Revolver 755 47 Less: unamortized debt discount and debt issuance costs (8,762) (11,665) 109,989 84,151 Less: DDB Revolver (755) (47) Less: current maturities of long-term debt (25,776) (6,934) Long-term debt $ 83,458 $ 77,170

Comprehensive Income (Tables)

Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income	The following table shows changes in accumulated other comprehensive income (“AOCI”) by component for the three and six months ended June 30, 2022 and 2021: Cumulative Foreign Currency Translation Unrealized Gains/(Losses) on Marketable Securities Total Balance at March 31, 2022 $ (441) $ (3,286) $ (3,727) Other comprehensive income (loss) before reclassifications 20 (4,393) (4,373) Amounts reclassified from AOCI — 1,022 1,022 Other comprehensive income 20 (3,371) (3,351) Balance at June 30, 2022 $ (421) $ (6,657) $ (7,078) Balance at December 31, 2021 $ (376) $ (727) $ (1,103) Other comprehensive income before reclassifications (45) (8,159) (8,204) Amounts reclassified from AOCI — 2,229 2,229 Other comprehensive income (loss) (45) (5,930) (5,975) Balance at June 30, 2022 $ (421) $ (6,657) $ (7,078) Balance at March 31, 2021 $ (451) $ (79) $ (530) Other comprehensive loss before reclassifications 70 358 428 Amounts reclassified from AOCI — (300) (300) Other comprehensive loss 70 58 128 Balance at June 30, 2021 $ (381) $ (21) $ (402) Balance at December 31, 2020 $ (380) $ 55 $ (325) Other comprehensive loss before reclassifications (1) 271 270 Amounts reclassified from AOCI — (347) (347) Other comprehensive loss (1) (76) (77) Balance at June 30, 2021 $ (381) $ (21) $ (402)

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Common Share Equivalents	The weighted average share impact of stock warrants, stock options, and restricted stock units that were excluded from the calculation of diluted shares outstanding due to the Company incurring a net loss for the three and six month periods ending June 30, 2022 and 2021 were as follows: Three Months Six Months Ended Anti-dilutive common share equivalents: 2022 2021 2022 2021 Warrants — 567 83 285 Stock options 3,813 7,369 4,266 5,676 Restricted stock units 5,285 — 4,102 — Total anti-dilutive common share equivalents 9,098 7,936 8,451 5,961
Schedule of Weighted Average Number of Shares	The following table provides the basis for basic and diluted EPS by outlining the numerators and denominators of the computations: Three Months Six Months Ended 2022 2021 2022 2021 Numerator: Net loss $ (27,554) $ (27,419) $ (44,130) $ (49,766) Denominator: Weighted average common shares outstanding, basic and diluted 185,530 109,222 173,189 108,989 Net loss per common share, basic and diluted $ (0.15) $ (0.25) $ (0.25) $ (0.46)

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Options Assumptions	The grant date fair value for the Company’s stock options granted under the 2012 Plan in the six months ended June 30, 2021 were based on the following assumptions used within the Black-Scholes option pricing model: 2021 Expected dividend yield 0 % Expected volatility 63 % Risk-free interest rate 0.7 % Expected term in years 6.1 years Weighted average grant date fair value $ 1.54

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Schedule of Segment Information	The Company had no intersegment revenues. Operating segment results for the three and six month periods ended June 30, 2022 and 2021 are presented below. Revenues Ingredients Fresh Unallocated and other Total Three Months Ended June 30, 2022 Domestic $ 91,144 $ 17,116 $ 86 $ 108,346 International 2,401 — — 2,401 Total $ 93,545 $ 17,116 $ 86 $ 110,747 Revenues Ingredients Fresh Unallocated and other Total Three Months Ended June 30, 2021 Domestic $ 22,724 $ 16,906 $ 62 $ 39,692 International — — — — Total $ 22,724 $ 16,906 $ 62 $ 39,692 Revenues Ingredients Fresh Unallocated and other Total Three Months Ended June 30, 2022 Point in time $ 93,545 $ 17,116 $ — $ 110,661 Over time — — 86 86 Total $ 93,545 $ 17,116 $ 86 $ 110,747 Revenues Ingredients Fresh Unallocated and other Total Three Months Ended June 30, 2021 Point in time $ 22,724 $ 16,906 $ 4 $ 39,634 Over time — — 58 58 Total $ 22,724 $ 16,906 $ 62 $ 39,692 Revenues Ingredients Fresh Unallocated and other Total Six Months Ended June 30, 2022 Domestic $ 155,565 $ 43,435 $ 139 $ 199,139 International 4,053 — — 4,053 Total $ 159,618 $ 43,435 $ 139 $ 203,192 Revenues Ingredients Fresh Unallocated and other Total Six Months Ended June 2021 Domestic $ 36,919 $ 34,470 $ 105 $ 71,494 International — — — — Total $ 36,919 $ 34,470 $ 105 $ 71,494 Revenues Ingredients Fresh Unallocated and other Total Six Months ended June 30, 2022 Point in time $ 159,618 $ 43,435 $ — $ 203,053 Over time — — 139 139 Total $ 159,618 $ 43,435 $ 139 $ 203,192 Revenues Ingredients Fresh Unallocated and other Total Six Months Ended June 30, 2021 Point in time $ 36,919 $ 34,470 $ 14 $ 71,403 Over time — — 91 91 Total $ 36,919 $ 34,470 $ 105 $ 71,494 Revenue Adjusted Three Months Ended June 30, 2022 Ingredients $ 93,545 $ (1,145) Fresh 17,116 (304) Unallocated and other 86 (14,217) Total segment results $ 110,747 $ (15,666) Adjustments to reconcile consolidated net loss to Adjusted EBITDA: Consolidated net loss $ (27,554) Interest expense, net 3,524 Income tax expense (benefit) 56 Depreciation and amortization 5,538 Stock-based compensation 5,676 Other expense (income), net 938 Change in fair value of warrants and conversion options (5,899) Other nonrecurring costs, including acquisition, transaction and integration costs 294 Non-recurring SOX readiness costs 70 Severance expense 124 Fresh segment crop failure costs 1,567 Total Adjusted EBITDA $ (15,666) Revenue Adjusted Three Months Ended June 30, 2021 Ingredients $ 22,724 $ (6,409) Fresh 16,906 165 Unallocated and other 62 (9,530) Total segment results $ 39,692 $ (15,774) Adjustments to reconcile consolidated net loss to Adjusted EBITDA: Consolidated net loss $ (27,419) Interest expense, net 1,277 Income tax (benefit) expense — Depreciation and amortization 2,839 Stock-based compensation 709 Other (income) expense, net (170) Change in fair value of warrants and conversion options 1,703 Other nonrecurring costs, including acquisition costs 527 South America seed production costs 2,805 Non-recurring public company readiness costs 1,955 Total Adjusted EBITDA $ (15,774) Revenue Adjusted Six Months Ended June 30, 2022 Ingredients $ 159,618 $ (16,040) Fresh 43,435 1,925 Unallocated and other 139 (29,083) Total segment results $ 203,192 $ (43,198) Adjustments to reconcile consolidated net loss to Adjusted EBITDA: Consolidated net loss $ (44,130) Interest expense, net 9,912 Income tax expense (benefit) 17 Depreciation and amortization 10,942 Stock-based compensation 11,359 Other expense (income), net 2,254 Change in fair value of warrants and conversion options (37,640) Other nonrecurring costs, including acquisition, transaction, and integration costs 312 Non-recurring SOX readiness costs 282 Severance expense 289 Fresh segment crop failure costs 1,567 PIPE Investment transaction costs 705 Fresh segment restructuring expenses 933 Total Adjusted EBITDA $ (43,198) Revenue Adjusted Six Months Ended June 30, 2021 Ingredients $ 36,919 $ (13,197) Fresh 34,470 (172) Unallocated and other 105 (17,252) Total segment results $ 71,494 $ (30,621) Adjustments to reconcile consolidated net loss to Adjusted EBITDA: Consolidated net loss $ (49,766) Depreciation and amortization 5,430 Stock-based compensation 1,356 Other (income) expense, net (388) Change in fair value of warrants and conversion options 2,719 Interest expense, net 2,535 Other nonrecurring items, including acquisition costs 527 South America seed production costs 2,805 Non-recurring public company readiness costs 4,161 Income tax expense (benefit) — Total Adjusted EBITDA $ (30,621)

Description of Business - Narra

Description of Business - Narratives (Details) - USD ($)		3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
Net loss		$ 27,554,000	$ 27,419,000	$ 44,130,000	$ 49,766,000
Net cash used in operating activities				58,732,000	47,257,000
Capital expenditures				5,637,000	21,128,000
Term debt and notes payable	$ 83,458,000	83,458,000		83,458,000		$ 77,170,000
Term debt and notes payable	109,989,000	109,989,000		109,989,000		84,151,000
Accumulated deficit	324,699,000	324,699,000		324,699,000		280,569,000
Cash and cash equivalents	46,772,000	46,772,000		46,772,000		78,963,000
Company drew amount				12,491,000	$ 14,451,000
Long-Term Debt
Debt Instrument [Line Items]
Term debt and notes payable	109,234,000	109,234,000		109,234,000
Convertible Notes Payable | Second tranche
Debt Instrument [Line Items]
Available borrowing	20,000,000	$ 20,000,000		$ 20,000,000		$ 20,000,000
Company drew amount	$ 20,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Narratives (Details)	Sep. 29, 2021
Accounting Policies [Abstract]
Exchange ratio	1.0754

Business Combinations - Narrati

Business Combinations - Narratives (Details) $ / shares in Units, $ in Thousands				3 Months Ended	6 Months Ended
	Dec. 30, 2021 USD ($)	Sep. 29, 2021 USD ($) $ / shares shares	Sep. 17, 2021 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 $ / shares shares	Sep. 28, 2021 $ / shares shares
Business Acquisition [Line Items]
Common stock, par value (in usd per share) | $ / shares		$ 0.0001			$ 0.0001		$ 0.0001
Exchange ratio		1.0754
Number of shares issued in transaction (in shares) | shares		22,500,000
Purchase price (in usd per share) | $ / shares		$ 10
Consideration received on transaction		$ 225,000
All classes of capital stock (in shares) | shares		441,000,000
Common stock, shares authorized (in shares) | shares		440,000,000			440,000,000		440,000,000
Preferred stock, shares authorized (in shares) | shares		1,000,000			1,000,000		1,000,000
Convertible preferred stock, par value (in shares) | $ / shares		$ 0.0001			$ 0.001		$ 0.001
Payments to acquire business					$ 1,034	$ 0
ZFS Creston, LLC
Business Acquisition [Line Items]
Payments to acquire business	$ 103,099
Working capital adjustment payment				$ 1,034
Identified intangible assets	11,000
ZFS Creston, LLC | Customer Relationships
Business Acquisition [Line Items]
Identified intangible assets	$ 5,500
Preliminary estimated useful life	15 years
ZFS Creston, LLC | Trade Names
Business Acquisition [Line Items]
Identified intangible assets	$ 2,000
Preliminary estimated useful life	10 years
ZFS Creston, LLC | Patented Technology
Business Acquisition [Line Items]
Identified intangible assets	$ 3,000
Preliminary estimated useful life	15 years
ZFS Creston, LLC | Permits
Business Acquisition [Line Items]
Identified intangible assets	$ 500
Preliminary estimated useful life	10 years
Rose Acre Farms
Business Acquisition [Line Items]
Total consideration			$ 14,567
Public Warrants
Business Acquisition [Line Items]
Warrants (in shares) | shares								10,063,000
Private Placement Warrants
Business Acquisition [Line Items]
Warrants (in shares) | shares								6,553,000
Legacy Benson Hill Common Stock
Business Acquisition [Line Items]
Common stock, par value (in usd per share) | $ / shares								$ 0.001

Business Combinations - Schedul

Business Combinations - Schedule of Acquired Assets and Liabilities (Details) - USD ($) $ in Thousands		6 Months Ended
	Dec. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Liabilities:
Payments to acquire business		$ 1,034	$ 0
ZFS Creston, LLC
Assets:
Cash and cash equivalents	$ 56
Accounts receivable	10,729
Inventories	18,209
Prepaid expenses and other current assets	3,627
Property and equipment	60,000
Right of use asset	853
Other assets	2,000
Identified intangible assets	11,000
Goodwill	7,079
Total assets acquired	113,553
Liabilities:
Accounts payable	4,661
Lease liability	853
Accrued expenses and other liabilities	4,940
Total liabilities assumed	10,454
Payments to acquire business	103,099
Total purchase price	$ 103,099

Fair Value Measurements - Narra

Fair Value Measurements - Narratives (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Cash and cash equivalents	$ 46,772	$ 78,963
Level 2
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contract asset		2,354
Contract liability		2,652
Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of long-term debt	$ 106,974	$ 85,163

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments Measured at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Liabilities
Conversion option liability	$ 10,940	$ 8,783
Corporate bonds
Assets
Debt securities	122,346	82,086
Preferred stock
Assets
Preferred stock	21,624	21,603
Recurring
Assets
Marketable securities	163,135	103,689
Liabilities
Total Warrant Liabilities	43,797	54,834
Recurring | U.S. treasury securities
Assets
Debt securities	19,166	0
Recurring | Corporate bonds
Assets
Debt securities	122,345	82,086
Recurring | Preferred stock
Assets
Preferred stock	21,624	21,603
Recurring | Corporate bonds
Liabilities
Warrant liabilities	32,857	46,051
Recurring | Conversion option liability
Liabilities
Conversion option liability	10,940	8,783
Recurring | Level 1
Assets
Marketable securities	19,166	0
Liabilities
Total Warrant Liabilities	4,729	12,377
Recurring | Level 1 | U.S. treasury securities
Assets
Debt securities	19,166	0
Recurring | Level 1 | Corporate bonds
Assets
Debt securities	0	0
Recurring | Level 1 | Preferred stock
Assets
Preferred stock	0	0
Recurring | Level 1 | Corporate bonds
Liabilities
Warrant liabilities	4,729	12,377
Recurring | Level 1 | Conversion option liability
Liabilities
Conversion option liability	0	0
Recurring | Level 2
Assets
Marketable securities	143,969	103,689
Liabilities
Total Warrant Liabilities	0	0
Recurring | Level 2 | U.S. treasury securities
Assets
Debt securities	0	0
Recurring | Level 2 | Corporate bonds
Assets
Debt securities	122,345	82,086
Recurring | Level 2 | Preferred stock
Assets
Preferred stock	21,624	21,603
Recurring | Level 2 | Corporate bonds
Liabilities
Warrant liabilities	0	0
Recurring | Level 2 | Conversion option liability
Liabilities
Conversion option liability	0	0
Recurring | Level 3
Assets
Marketable securities	0	0
Liabilities
Total Warrant Liabilities	39,068	42,457
Recurring | Level 3 | U.S. treasury securities
Assets
Debt securities	0	0
Recurring | Level 3 | Corporate bonds
Assets
Debt securities	0	0
Recurring | Level 3 | Preferred stock
Assets
Preferred stock	0	0
Recurring | Level 3 | Corporate bonds
Liabilities
Warrant liabilities	28,128	33,674
Recurring | Level 3 | Conversion option liability
Liabilities
Conversion option liability	$ 10,940	$ 8,783

Fair Value Measurements - Unobs

Fair Value Measurements - Unobservable Input Reconciliation (Details) - Total liabilities - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	$ 45,169	$ 6,257	$ 42,457	$ 5,241
Change in estimated fair value	(6,101)	1,703	(29,993)	2,719
Issuance of PIPE Investment warrants	0		26,604
Ending balance	$ 39,068	$ 7,960	$ 39,068	$ 7,960

Investments in Available-for-_3

Investments in Available-for-Sale Securities - Summary of Securities Classified as Available-for-Sale (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Equity Securities, FV-NI [Abstract]
Cost Basis	$ 171,483	$ 103,560
Gross Unrealized Gains	52	698
Gross Unrealized Losses	(8,400)	(569)
Fair Value	163,135	103,689
U.S government and agency securities
Debt Securities
Cost Basis	19,191	0
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(26)	0
Fair Value	19,165	0
Corporate notes and bonds
Debt Securities
Cost Basis	127,952	82,007
Gross Unrealized Gains	52	572
Gross Unrealized Losses	(5,658)	(493)
Fair Value	122,346	82,086
Preferred stock
Equity Securities, FV-NI [Abstract]
Cost Basis	24,340	21,553
Gross Unrealized Gains	0	126
Gross Unrealized Losses	(2,716)	(76)
Fair Value	$ 21,624	$ 21,603

Investments in Available-for-_4

Investments in Available-for-Sale Securities - Narratives (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Fair value of investments with unrealized losses, less than a year	$ 146,997,000	$ 48,098,000
Fair value of investments with unrealized losses, more than a year	0	$ 0
Marketable securities with maturity one year	75,118,000
Marketable securities maturity one to five years	$ 88,017,000

Derivatives - Narratives (Detai

Derivatives - Narratives (Details) lb in Thousands, bu in Thousands, T in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) bu	Jun. 30, 2022 USD ($) lb	Jun. 30, 2022 USD ($) T	Dec. 31, 2021 USD ($)
Price Risk Derivatives [Line Items]
Fair value, cash-settled on a daily basis | $	$ 0	$ 0	$ 0
Current asset representing excess cash collateral posted to a margin account | $	$ 3,568,000	$ 3,568,000	$ 3,568,000	$ 2,504,000
Soybeans
Price Risk Derivatives [Line Items]
Financial futures	6,025
Aggregate notional volume		563	103
Soybean contract, settling in current year
Price Risk Derivatives [Line Items]
Financial futures	4,345
Soybean contract, settling next year
Price Risk Derivatives [Line Items]
Financial futures	1,680

Derivatives - Derivative Contra

Derivatives - Derivative Contracts (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Asset Derivative
Effect of daily cash settlement	$ (6,389)	$ (23)
Net derivatives as classified in the balance sheet	0	0
Liability Derivative
Effect of daily cash settlement	(5,456)	(1,277)
Net derivatives as classified in the balance sheet	0	0
Soybeans
Asset Derivative
Soybeans	3,019	18
Liability Derivative
Soybeans	1,839	48
Soybean oil
Asset Derivative
Soybeans	2,208	5
Liability Derivative
Soybeans	1,998	1
Soybean meal
Asset Derivative
Soybeans	1,162	0
Liability Derivative
Soybeans	$ 1,619	$ 1,228

Derivatives - Pre-tax Gains and

Derivatives - Pre-tax Gains and Losses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Derivative [Line Items]
Revenues	$ 110,747	$ 39,692	$ 203,192	$ 71,494
Cost of Goods and Services Sold	(105,171)	(39,722)	(202,838)	(70,955)
Not Designated as Hedging Instrument | Sales
Derivative [Line Items]
Total gain (loss) recognized in income	528	316	(6,671)	856
Not Designated as Hedging Instrument | Cost of Sales
Derivative [Line Items]
Total gain (loss) recognized in income	327	(263)	(5,020)	(1,368)
Soybeans | Not Designated as Hedging Instrument | Sales
Derivative [Line Items]
Total gain (loss) recognized in income	0	0	0	0
Soybeans | Not Designated as Hedging Instrument | Cost of Sales
Derivative [Line Items]
Total gain (loss) recognized in income	327	(263)	(5,020)	(1,368)
Soybean oil | Not Designated as Hedging Instrument | Sales
Derivative [Line Items]
Total gain (loss) recognized in income	(775)	316	(7,198)	856
Soybean oil | Not Designated as Hedging Instrument | Cost of Sales
Derivative [Line Items]
Total gain (loss) recognized in income	0	0	0	0
Soybean meal | Not Designated as Hedging Instrument | Sales
Derivative [Line Items]
Total gain (loss) recognized in income	1,303	0	527	0
Soybean meal | Not Designated as Hedging Instrument | Cost of Sales
Derivative [Line Items]
Total gain (loss) recognized in income	$ 0	$ 0	$ 0	$ 0

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 18,433	$ 20,578
Work-in-process	7,392	11,580
Finished goods	21,941	16,566
Total inventories	$ 47,766	$ 48,724

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 146,201,000		$ 146,201,000		$ 142,535,000
Less accumulated depreciation	(21,439,000)		(21,439,000)		(15,650,000)
Property and equipment, net	124,762,000		124,762,000		126,885,000
Depreciation	3,361,000	$ 2,839,000	6,643,000	$ 3,564,000
Capitalized interest costs	385,000	$ 516,000	782,000	$ 771,000
Impairment charges			0
Aggregate carrying value			40,410,000
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	8,026,000		8,026,000		8,026,000
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,642,000		3,642,000		3,116,000
Machinery, field, and laboratory equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	81,528,000		81,528,000		81,119,000
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,641,000		2,641,000		2,545,000
Vehicles
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,112,000		3,112,000		2,660,000
Buildings and building improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	25,882,000		25,882,000		26,911,000
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 21,370,000		$ 21,370,000		$ 18,158,000

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 7,142	$ 9,325
Contract asset	1,973	2,588
Derivative margin asset	3,568	3,273
Tax receivable	913	2,254
Deposits	617	650
Commitment asset	0	416
Other	331	1,747
Prepaid expenses and other current assets	$ 14,544	$ 20,253

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Payroll and employee benefits	$ 7,941	$ 9,144
Insurance premiums	657	4,099
Professional services	1,619	2,517
Research and development	1,282	1,043
Inventory	10,013	3,168
Interest	124	178
PIPE Investment transaction costs	178	0
Contract liability	1,065	2,652
Other	4,544	3,970
Total	$ 27,423	$ 26,771

Debt - Schedule of Long-term De

Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Less: unamortized debt discount and debt issuance costs	$ (8,762)	$ (11,665)
Long-term debt	109,989	84,151
Current maturities of long-term debt	(25,776)	(6,934)
Long-term debt	83,458	77,170
Long-Term Debt
Debt Instrument [Line Items]
Long-term debt	109,234
Current maturities of long-term debt	(25,776)	(6,934)
Secured Debt | Equipment Financing, due March 2025
Debt Instrument [Line Items]
Long-term debt	3,781	0
Convertible Notes Payable | Convertible Notes Payable, due January 2025
Debt Instrument [Line Items]
Long-term debt	102,518	80,000
Convertible Notes Payable | Creston Note Payable, due August 2022
Debt Instrument [Line Items]
Long-term debt	1,667	5,000
Notes Payable | Notes payable, varying maturities through June 2026
Debt Instrument [Line Items]
Long-term debt	493	313
Revolving credit facility | DDB Revolver
Debt Instrument [Line Items]
Current maturities of long-term debt	(755)	(47)
Revolving credit facility | Secured Debt | DDB Term loan, due April 2024
Debt Instrument [Line Items]
Long-term debt	7,962	8,531
Revolving credit facility | Secured Debt | DDB Equipment loan, due July 2024
Debt Instrument [Line Items]
Long-term debt	1,575	1,925
Revolving credit facility | Revolving credit facility | DDB Revolver
Debt Instrument [Line Items]
Long-term debt	$ 755	$ 47

Debt - Narratives (Details)

Debt - Narratives (Details)			1 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2022 USD ($)	Apr. 30, 2019 USD ($)	Dec. 31, 2021 USD ($) d $ / shares	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)
Debt Instrument [Line Items]
Borrowing under revolving line of credit					$ 12,491,000	$ 14,451,000
Secured Debt | Credit Agreement
Debt Instrument [Line Items]
Maximum amount guaranteed	$ 7,000,000				7,000,000
Secured Debt | Credit Agreement | DDB Term Loan
Debt Instrument [Line Items]
Aggregate principal amount		$ 14,000,000
Debt term		5 years
Equal quarterly installments					284,000
Remaining balance	$ 5,972,000				5,972,000
Secured Debt | Credit Agreement | DDB Equipment loan, due July 2024
Debt Instrument [Line Items]
Aggregate principal amount		$ 3,500,000
Equal quarterly installments					$ 175,000
Secured Debt | Credit Agreement | DDB Term Loan and DDB Equipment Loan
Debt Instrument [Line Items]
Interest rate	5.50%				5.50%
Secured Debt | Credit Agreement | DDB Term Loan and DDB Equipment Loan | Prime Rate
Debt Instrument [Line Items]
Variable rate					0.75%
Credit Agreement | Credit Agreement | DDB Revolver
Debt Instrument [Line Items]
Interest rate	5%				5%
Credit Agreement | Credit Agreement | DDB Revolver | Prime Rate
Debt Instrument [Line Items]
Variable rate					0.25%
Revolver | Credit Agreement | DDB Revolver
Debt Instrument [Line Items]
Available borrowing		$ 6,000,000
Convertible Notes Payable | Convertible Loan and Security Agreement
Debt Instrument [Line Items]
Available borrowing			$ 100,000,000
Remaining balance			10,700,000
Available borrowing			$ 80,000,000
Milestone achievement revenue			85%
Gross margin			(1.50%)
Market capitalization			$ 650,000,000
Trailing days			30 days
Borrowing under revolving line of credit			$ 80,000,000
Milestone achievement extension			36 months
Interest only extension term			12 months
Final payment			$ 14,200,000
Debt redemption maximum			$ 20,000,000
Consecutive trading days | d			7
Trading volume conversion maximum			20%
Consecutive trading days | d			22
Shares outstanding conversion maximum			2.50%
Conversion option			$ 8,783,000
Minimum liquidity, equal to or greater than			6 months
Convertible Notes Payable | Convertible Loan and Security Agreement | Achievement of certain milestones
Debt Instrument [Line Items]
Milestone achievement extension			42 months
Convertible Notes Payable | Convertible Loan and Security Agreement | First period
Debt Instrument [Line Items]
Interest only extension term					7 months
Monthly interest payment					$ 870,000
Conversion stock price (in usd per share) | $ / shares			$ 2.47
Convertible Notes Payable | Convertible Loan and Security Agreement | Second period
Debt Instrument [Line Items]
Stated rate			5.75%
Interest only extension term			12 months		24 months
Principal and interest installment					$ 4,591,000
Gross proceeds			$ 20,000,000
Common stock trading day | d			14
Convertible Notes Payable | Convertible Loan and Security Agreement | Third period
Debt Instrument [Line Items]
Interest only extension term			24 months
Convertible Notes Payable | Convertible Loan and Security Agreement | Minimum
Debt Instrument [Line Items]
Prepayment fee			1%
conversion term			6 months
Convertible Notes Payable | Convertible Loan and Security Agreement | Maximum
Debt Instrument [Line Items]
Prepayment fee			6%
conversion term			42 months
Convertible Notes Payable | Convertible Loan and Security Agreement | Prime Rate
Debt Instrument [Line Items]
Variable rate			3.25%
Convertible Notes Payable | Second tranche
Debt Instrument [Line Items]
Available borrowing	$ 20,000,000		$ 20,000,000		$ 20,000,000
Available borrowing			$ 20,000
Borrowing under revolving line of credit	$ 20,000,000
Interest only extension term			24 months
Notes Payable
Debt Instrument [Line Items]
Equity financing liability amount				$ 4,078,000
Proceeds recorded as financing liability				$ 133,000
Financing arrangement term				36 months
Notes Payable | Creston Note Payable
Debt Instrument [Line Items]
Aggregate principal amount			$ 5,000,000
Stated rate			3%
Notes Payable | Creston Note Payable | Minimum
Debt Instrument [Line Items]
Equal quarterly installments			$ 833,000

Warrant Liabilities - Narrative

Warrant Liabilities - Narratives (Details)

1 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2022 USD ($) $ / shares shares

Sep. 29, 2021 $ / shares shares

Sep. 28, 2021 $ / shares shares

Jan. 08, 2021 d $ / shares shares

Mar. 31, 2022 USD ($) $ / shares shares

Dec. 31, 2021 USD ($) d $ / shares

Feb. 29, 2020 USD ($) $ / shares shares

Mar. 31, 2022 d $ / shares shares

Jun. 30, 2022 USD ($) $ / shares shares

Jun. 30, 2021 USD ($)

Sep. 30, 2021 USD ($)

Jan. 08, 2018 shares

Class of Stock [Line Items]

Exchange ratio

1.0754

Shares issued (in shares) | shares

350,000

Common stock, par value (in usd per share) | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.0001

Borrowing under revolving line of credit

$ 12,491,000

$ 14,451,000

PIPE Investment

Class of Stock [Line Items]

Transaction costs

$ 4,161,000

IPO | STPC

Class of Stock [Line Items]

Units issued (in shares) | shares

40,250,000

Notes Payable | Loan and Security Agreement

Class of Stock [Line Items]

Aggregate principal amount

$ 20,000,000

Notes Payable | Loan and Security Agreement, second tranche

Class of Stock [Line Items]

Available borrowing

$ 15,000,000

Notes Payable | New Loan and Security Agreement

Class of Stock [Line Items]

Aggregate principal amount

$ 20,000

Available borrowing

20,000

Notes Payable | New Loan and Security Agreement, Remaining Commitment

Class of Stock [Line Items]

Available borrowing

20,000

Convertible Notes Payable | Second tranche

Class of Stock [Line Items]

Available borrowing

$ 20,000

Borrowing under revolving line of credit

$ 20,000,000

Convertible Notes Payable | Convertible Loan and Security Agreement

Class of Stock [Line Items]

Available borrowing

80,000,000

Borrowing under revolving line of credit

$ 80,000,000

New Benson Hill Common Stock | IPO | STPC

Class of Stock [Line Items]

Shares issued per unit (in shares) | shares

1

Legacy Benson Hill Common Stock

Class of Stock [Line Items]

Common stock, par value (in usd per share) | $ / shares

$ 0.001

Warrants To Purchase Preferred Stock | Series C-1 and other preferred shares

Class of Stock [Line Items]

Warrants issued (in shares) | shares

1,077,000

Warrants To Purchase New Benson Hill Common Stock | New Benson Hill Common Stock

Class of Stock [Line Items]

Warrants (in shares) | shares

1,158,000

Warrant exercise price (in usd per share) | $ / shares

$ 9.30

$ 3.43

Warrants exchanged for shares (in shares) | shares

242,000

Warrant exercise price (in usd per share) | $ / shares

$ 10

Warrants issued (in shares) | shares

225,000

Warrants To Purchase New Benson Hill Common Stock | New Benson Hill Common Stock | Notes Payable | Loan and Security Agreement

Class of Stock [Line Items]

Warrants liability (asset) fair value

$ 3,332,000

Warrants To Purchase New Benson Hill Common Stock | New Benson Hill Common Stock | Notes Payable | Loan and Security Agreement, second tranche

Class of Stock [Line Items]

Warrants liability (asset) fair value

$ 1,248,000

Warrants to purchase common or Series D preferred stock | Common stock, Series D preferred shares, or any subsequent preferred shares | Notes Payable | New Loan and Security Agreement

Class of Stock [Line Items]

Warrants liability (asset) fair value

3,523,000

Warrants to purchase common or Series D preferred stock | Common stock, Series D preferred shares, or any subsequent preferred shares | Notes Payable | New Loan and Security Agreement, Remaining Commitment

Class of Stock [Line Items]

Warrants liability (asset) fair value

$ 1,028,000

Warrants For Legacy Benson Hill Common Stock | Legacy Benson Hill Common Stock

Class of Stock [Line Items]

Warrants exchanged for shares (in shares) | shares

325,000

Convertible Notes Payable Warrants

Class of Stock [Line Items]

Warrant exercise price (in usd per share) | $ / shares

$ 2.47

Aggregate number of shares numerator

$ 3,000,000

Gross proceeds

$ 20,000,000

Consecutive trading days | d

14

Fair value of warrants

$ 1,690,000

Convertible Notes Payable Warrants, Second Tranche

Class of Stock [Line Items]

Fair value of warrants

$ 423,000

PIPE Investment Warrants | PIPE Investment

Class of Stock [Line Items]

Warrants (in shares) | shares

8,716,000

8,716,000

Units issued (in shares) | shares

26,150

Units issued (in usd per share) | $ / shares

$ 3.25

$ 3.25

Aggregate purchase price

$ 85,000,000

Transaction costs

$ 705,000

Warrant transaction costs (in shares) | shares

362,000

362,000

Maximum share increase percent

19.99%

PIPE Investment Warrants | PIPE Investment | Redemption, stock equals or exceeds $18.00

Class of Stock [Line Items]

Warrant exercise price (in usd per share) | $ / shares

$ 3.90

3.90

PIPE Investment Warrants | PIPE Investment | Redemption, stock equals or exceeds $10.00

Class of Stock [Line Items]

Warrant exercise price (in usd per share) | $ / shares

9.75

9.75

Warrant redemption, price per common stock (in usd per share) | $ / shares

$ 0.10

$ 0.10

Trading period after business combination used to measure dilution of warrant | d

20

Number of trading days for determining the share price | d

30

PIPE Investment Warrants | New Benson Hill Common Stock | PIPE Investment

Class of Stock [Line Items]

Shares issued per unit (in shares) | shares

1

Public Warrants and Private Placement Warrants

Class of Stock [Line Items]

Trading period after business combination used to measure dilution of warrant | d

10

Number of days prior to the date of notifying the warrant holders for determining the total trading period

3 days

Public Warrants and Private Placement Warrants | Redemption, stock equals or exceeds $18.00

Class of Stock [Line Items]

Warrant redemption, price per common stock (in usd per share) | $ / shares

$ 18

Trading period after business combination used to measure dilution of warrant | d

20

Number of trading days for determining the share price | d

30

Number of days of notice to be given for the redemption of warrants

30 days

Warrant redemption period

30 days

Number of days prior to the date of notifying the warrant holders for determining the total trading period

3 years

Public Warrants and Private Placement Warrants | Redemption, stock equals or exceeds $10.00

Class of Stock [Line Items]

Warrant redemption, price per common stock (in usd per share) | $ / shares

$ 10

Trading period after business combination used to measure dilution of warrant | d

20

Number of trading days for determining the share price | d

30

Number of days prior to the date of notifying the warrant holders for determining the total trading period

3 days

3 days

Public Warrants and Private Placement Warrants | New Benson Hill Common Stock | Maximum

Class of Stock [Line Items]

Shares of common stock per warrant (in shares) | shares

0.361

Public Warrants and Private Placement Warrants | New Benson Hill Common Stock | Redemption, stock equals or exceeds $18.00

Class of Stock [Line Items]

Warrant exercise price (in usd per share) | $ / shares

$ 0.01

Public Warrants and Private Placement Warrants | New Benson Hill Common Stock | Redemption, stock equals or exceeds $10.00

Class of Stock [Line Items]

Warrant exercise price (in usd per share) | $ / shares

$ 0.10

Public Warrants

Class of Stock [Line Items]

Warrants (in shares) | shares

10,063,000

Warrants term

5 years

Public Warrants | IPO

Class of Stock [Line Items]

Shares of common stock per warrant (in shares) | shares

0.25

Public Warrants | New Benson Hill Common Stock

Class of Stock [Line Items]

Warrant exercise price (in usd per share) | $ / shares

$ 11.50

Public Warrants | New Benson Hill Common Stock | IPO | STPC

Class of Stock [Line Items]

Warrants (in shares) | shares

10,063,000

Private Placement Warrants

Class of Stock [Line Items]

Warrants (in shares) | shares

6,553,000

Private Placement Warrants | New Benson Hill Common Stock | IPO | STPC

Class of Stock [Line Items]

Warrants (in shares) | shares

6,553,000

Income Taxes - Narratives (Deta

Income Taxes - Narratives (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Effective income tax rate	0%	0%	0%	0%

Comprehensive Income (Details)

Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 293,494	$ 110,846	$ 251,447	$ 132,682
Other comprehensive income (loss) before reclassifications	(4,373)	428	(8,204)	270
Amounts reclassified from AOCI	1,022	(300)	2,229	(347)
Total other comprehensive (loss) income	(3,351)	128	(5,975)	(77)
Ending balance	268,980	84,673	268,980	84,673
Cumulative Foreign Currency Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(441)	(451)	(376)	(380)
Other comprehensive income (loss) before reclassifications	20	70	(45)	(1)
Amounts reclassified from AOCI	0	0	0	0
Total other comprehensive (loss) income	20	70	(45)	(1)
Ending balance	(421)	(381)	(421)	(381)
Unrealized Gains/(Losses) on Marketable Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(3,286)	(79)	(727)	55
Other comprehensive income (loss) before reclassifications	(4,393)	358	(8,159)	271
Amounts reclassified from AOCI	1,022	(300)	2,229	(347)
Total other comprehensive (loss) income	(3,371)	58	(5,930)	(76)
Ending balance	(6,657)	(21)	(6,657)	(21)
AOCI Attributable to Parent
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(3,727)	(530)	(1,103)	(325)
Ending balance	$ (7,078)	$ (402)	$ (7,078)	$ (402)

Loss Per Common Share - Anti-di

Loss Per Common Share - Anti-dilutive Common Share Equivalents (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents (in shares)	9,098	7,936	8,451	5,961
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents (in shares)	0	567	83	285
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents (in shares)	3,813	7,369	4,266	5,676
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents (in shares)	5,285	0	4,102	0

Loss Per Common Share - Weighte

Loss Per Common Share - Weighted Average Basic and Diluted Common Shares (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator:
Net loss	$ (27,554)	$ (27,419)	$ (44,130)	$ (49,766)
Denominator:
Weighted average common shares outstanding, basic (in shares)	185,530	109,222	173,189	108,989
Weighted average common shares outstanding, diluted (in shares)	185,530	109,222	173,189	108,989
Net loss per common share, basic (in usd per share)	$ (0.15)	$ (0.25)	$ (0.25)	$ (0.46)
Net loss per common share, diluted (in usd per share)	$ (0.15)	$ (0.25)	$ (0.25)	$ (0.46)

Stock-Based Compensation - Narr

Stock-Based Compensation - Narratives (Details) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2022 USD ($) d $ / shares shares	Jun. 30, 2021 USD ($) shares	Jun. 12, 2012 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options nonvested (in shares) | shares	4,514,000	8,958,000	4,514,000	8,958,000
Stock-based compensation | $	$ 5,676	$ 709	$ 11,359	$ 1,356
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share conversion ratio			1
Restricted stock units | Time-based Vesting Conditions
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options nonvested (in shares) | shares	5,211		5,211
Restricted stock units | Time and Market Based Performance Vesting Conditions
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options nonvested (in shares) | shares	4,424		4,424
Restricted Stock Units RSU, Earnout Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Approved issuance (in shares) | shares			1,431
Restricted Stock Units RSU, Earnout Awards | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual life			36 months
Award vesting percentage			50%
Common stock vesting trigger price (in usd per share)	$ 14		$ 14
Trading days | d			20
Consecutive trading days | d			30
Restricted Stock Units RSU, Earnout Awards | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual life			36 months
Award vesting percentage			50%
Common stock vesting trigger price (in usd per share)	16		$ 16
Trading days | d			20
Consecutive trading days | d			30
Restricted Stock Units RSU, Executive Founders Grants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Approved issuance (in shares) | shares			993
Award vesting percentage			100%
Restricted Stock Units RSU, Executive Founders Grants | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage			50%
Common stock vesting trigger price (in usd per share)	15		$ 15
Volume weighted average period			30 days
Restricted Stock Units RSU, Executive Founders Grants | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage			50%
Common stock vesting trigger price (in usd per share)	20		$ 20
Restricted Stock Units RSU, Executive Founders Grants | Share-Based Payment Arrangement, Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock vesting trigger price (in usd per share)	16.50		$ 16.50
Target increased percentage			10%
Restricted Stock Units RSU, CEO Founders Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Approved issuance (in shares) | shares			2,000
Award vesting percentage			100%
Volume weighted average period			30 days
Restricted Stock Units RSU, CEO Founders Grant | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage			25%
Common stock vesting trigger price (in usd per share)	15		$ 15
Volume weighted average period			30 days
Restricted Stock Units RSU, CEO Founders Grant | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage			25%
Common stock vesting trigger price (in usd per share)	20		$ 20
Volume weighted average period			30 days
Restricted Stock Units RSU, CEO Founders Grant | Share-Based Payment Arrangement, Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage			25%
Common stock vesting trigger price (in usd per share)	25		$ 25
Volume weighted average period			30 days
Restricted Stock Units RSU, CEO Founders Grant | Share-based Payment Arrangement, Tranche Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage			25%
Common stock vesting trigger price (in usd per share)	$ 30		$ 30
Volume weighted average period			30 days
Restricted Stock Units RSU, CEO Founders Grant | Share-based Payment Arrangement, Tranche Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target increased percentage			10%
The Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards issued (in shares) | shares			16,502,000
2012 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock reserved for issuance (in shares) | shares	10,317,000		10,317,000		17,464,000
2012 Plan | Stock option awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Contractual life			10 years
2012 Plan | Stock option awards | Board members
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			2 years

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock Options Assumptions (Details) - Stock option awards	6 Months Ended
	Jun. 30, 2021 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0%
Expected volatility	63%
Risk-free interest rate	0.70%
Expected term in years	6 years 1 month 6 days
Weighted average grant date fair value (in usd per share)	$ 1.54

Commitments and Contingencies -

Commitments and Contingencies - Narratives (Details) bu in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) bu	Dec. 31, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Liability accrual	$ 0	$ 0
Inventory	$ 71,800
Purchase commitment (bushels) | bu	625

Segment Information - Narrative

Segment Information - Narratives (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 110,747,000	$ 39,692,000	$ 203,192,000	$ 71,494,000
Intersegment Eliminations
Disaggregation of Revenue [Line Items]
Revenues	$ 0	$ 0	$ 0	$ 0

Segment Information - Schedule

Segment Information - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$ 110,747	$ 39,692	$ 203,192	$ 71,494
Total Adjusted EBITDA	(15,666)	(15,774)	(43,198)	(30,621)
Operating Income (Loss) [Abstract]
Consolidated net loss	(27,554)	(27,419)	(44,130)	(49,766)
Interest expense, net	3,524	1,277	9,912	2,535
Income tax expense (benefit)	56	0	17	0
Depreciation and amortization	5,538	2,839	10,942	5,430
Stock-based compensation	5,676	709	11,359	1,356
Other expense (income), net	938	(170)	2,254	(388)
Change in fair value of warrants and conversion options	(5,899)	1,703	(37,640)	2,719
Other nonrecurring costs, including acquisition, transaction and integration costs	294	527	312	527
Non-recurring SOX readiness costs	70		282
Severance expense	124		289
Fresh segment crop failure costs	1,567		1,567
PIPE Investment transaction costs			705
Fresh segment restructuring expenses			933
South America seed production costs		2,805		2,805
Non-recurring public company readiness costs		1,955		4,161
Domestic
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	108,346	39,692	199,139	71,494
International
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	2,401	0	4,053	0
Point in time
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	110,661	39,634	203,053	71,403
Over time
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	86	58	139	91
Unallocated and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	86	62	139	105
Total Adjusted EBITDA	(14,217)	(9,530)	(29,083)	(17,252)
Unallocated and other | Domestic
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	86	62	139	105
Unallocated and other | International
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	0	0	0	0
Unallocated and other | Point in time
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	0	4	0	14
Unallocated and other | Over time
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	86	58	139	91
Ingredients | Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	93,545	22,724	159,618	36,919
Total Adjusted EBITDA	(1,145)	(6,409)	(16,040)	(13,197)
Ingredients | Operating Segments | Domestic
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	91,144		155,565	36,919
Ingredients | Operating Segments | International
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	2,401	0	4,053	0
Ingredients | Operating Segments | Point in time
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	93,545	22,724	159,618	36,919
Ingredients | Operating Segments | Over time
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	0	0	0	0
Fresh | Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	17,116	16,906	43,435	34,470
Total Adjusted EBITDA	(304)	165	1,925	(172)
Fresh | Operating Segments | Domestic
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	17,116		43,435	34,470
Fresh | Operating Segments | International
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	0	0	0	0
Fresh | Operating Segments | Point in time
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	17,116	16,906	43,435	34,470
Fresh | Operating Segments | Over time
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$ 0	$ 0	$ 0	$ 0

Subsequent Events (Details)

Subsequent Events (Details) - $ / shares	Jul. 21, 2022	Jun. 30, 2022	Dec. 31, 2021	Sep. 29, 2021
Subsequent Event [Line Items]
Common stock, shares authorized (in shares)		440,000,000	440,000,000	440,000,000
Common stock, par value (in usd per share)		$ 0.0001	$ 0.0001	$ 0.0001
Subsequent Event | 2022 Employee Stock Purchase Plan
Subsequent Event [Line Items]
Common stock, shares authorized (in shares)	5,000,000
Common stock, par value (in usd per share)	$ 0.0001